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brane-anchoring glycolipid structure induces the sequential 
transport of proteins from special regions of the plasma 
membrane via the surface of intracellular lipid droplets to 
special membrane vesicles, which are finally released from 
the adipocytes together with the associated GPI proteins. It 
remains to be studied whether similar molecular mecha-
nisms operate in intestinal epithelial cells and may enable 
the transport of GPI proteins from the intestinal lumen into 
the blood stream. If so, modification of proteins encoded by 
(combinations of) susceptibility genes with GPI could signif-
icantly facilitate the personalized therapy of common dis-
eases on the basis of ‘inborn’ safety, efficacy, rapid realiza-
tion and oral application.  Copyright © 2010 S. Karger AG, Basel 
 Introduction – Personalized Therapy 
 During the past decade, knowledge about the involve-
ment of a multitude of susceptibility genes and novel 
complete mechanisms in the pathogenesis of complex 
and common multifactorial diseases, such as type II dia-
betes, has been accumulating  [1–4] . Nevertheless, cur-
rently these novel findings have not been translated into 
corresponding methods and technologies for their prog-
nosis and diagnosis  [5] . This may be due to the relatively 
 Key Words 
 Protein therapeutics   Oral delivery   Personalized 
medicine   Post-translational modification   Protein 
trafficking 
 Abstract 
 The reliable and early diagnosis of common complex multi-
factorial diseases depends on the individual determination 
of all (or as many as possible) polymorphisms of each suscep-
tibility gene together with amount and type of the corre-
sponding gene products and their downstream effects, in-
cluding the synthesis and flux of metabolites and regulation 
of signalling processes. In addition, this system’s biology-
driven personalized diagnosis must be accompanied by op-
tions for personalized reliable and early therapy. In the mid-
term, the direct substitution or inhibition of the proteins en-
coded by the corresponding defective gene products of the 
susceptibility genes exerting lower or higher activity by ad-
ministration of the ‘normal’ proteins or inhibitory antibodies, 
respectively, seems to be most promising. The critical hurdle 
of oral bioavailability as well as transport into the cytoplasm 
of the target cells, if required, could be overcome by thera-
peutic proteins with carboxy-terminal modification by gly-
cosylphosphatidylinositol (GPI). This may be deduced from 
recent experiments with rat adipocytes. Here this mem-
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moderate predictive power derived from the determina-
tion of the individual complete genetic profile (genomics) 
which, in part, is caused by inadequate numbers of (com-
binations of) (single nucleotide) polymorphisms identi-
fied in susceptibility genes so far  [6, 7] . For principal rea-
sons this obstacle cannot be overcome by a mere increase 
in sample size  [8, 9] . However, it may be weakened by the 
inclusion of additional ‘downstream parameters’ encom-
passing the complete patterns of proteins (proteomics), 
lipids (lipidomics), metabolites (metabolomics) and their 
fluxes (fluxomics) of the patient versus control subject  [5, 
10–12] . Unfortunately, the present technologies for ge-
nomics, proteomics, lipidomics and metabolomics are 
relatively cost-intensive. Nevertheless, this burden would 
be accepted facing the enormous social and economical 
consequences for the community and the health prob-
lems for the affected individual patient, which are associ-
ated in the long term with common complex diseases, in 
general, and type II diabetes, in particular. However, the 
acceptance by the society for the need of a timely and re-
liable diagnosis is based on the availability of adequate 
options for prevention and therapy, which may include, 
but must not be limited to, advices for a (more) healthy 
life style, such as food restriction and intensified physical 
exercise (albeit there is no doubt about their benefit for 
the prevention of the majority of common diseases in the 
Western countries). Clearly the expenditure for personal-
ized diagnosis, which has to be supported by all (affected 
as well as non-affected) members of our health care sys-
tems, cannot be justified by the currently implemented 
strategies of non-personalized prevention and therapy. 
They simply divide the population into normal (‘control’) 
and affected (‘case’), and recommend first-, second- and 
third-line (or more) treatments. For example, the therapy 
of type II diabetes is currently based on 6 approved drug 
classes encompassing both small molecules (metformin, 
sulfonylureas, glitazones, DPP-IV inhibitors) and (un-
modified or modified) proteins (insulin and analogues, 
glucagon-like polypeptide-I and analogues). Certainly, 
this repertoire does not meet the requirements for the in-
dividualized treatment of this common disease with its 
estimated 2,000–3,000 susceptibility genes and even 
higher numbers of the underlying polymorphisms and 
combinations thereof. The resulting heterogeneity is fur-
ther amplified by individual polymorphisms in protec-
tive genes and positive or negative environmental influ-
ences  [5] . Thus, the currently available therapies for com-
mon complex diseases do not fit to the multitude and 
heterogeneity of the underlying disease mechanisms.
 Traditional Options for Therapy 
 Which options for personalized therapy are currently 
in our hands, at least in principle ( fig. 1 )? (1) The abnor-
mal function or synthesis of a polymorphic/mutant gene 
product encoded by the susceptibility gene may be cor-
rected (that is, inhibited/activated or down-/upregulated) 
by orally available small drug molecules. (2) The poly-
morphic/mutant variant of the susceptibility gene may
be replaced by the corresponding wild-type genes (gene 
therapy). (3) The abnormal tissues/cells suffering from 
the expression of the polymorphic/mutant variant of the 
susceptibility gene may be replaced by normal tissues/
cells grown in culture (regenerative medicine and tissue 
engineering). (4) The missing or overactive function or 
synthesis of a polymorphic/mutant gene product encod-
ed by the susceptibility gene may be compensated for by 
delivery of the wild-type gene product or neutralizing an-
tibodies against the corresponding polymorphic/mutant 
gene product (protein therapeutics and therapeutic anti-
bodies ( fig. 1 ). Each of these strategies will lead to person-
alized therapy for a given complex common disease, that 
is, tailored to the individual genetic profile and individ-
ual complete pathogenic mechanism. In case of type II 
diabetes, these strategies may target components of the 
glucose-sensing system in pancreatic   cells and intesti-
nal L cells, insulin production and secretion in the   cells, 
or insulin action in muscle, adipose and/or liver cells or 
combinations thereof.
 By nature, there are advantages and disadvantages as-
sociated with each of these therapeutic strategies, which 
are only outlined here in brief ( fig. 1 ). Gene therapy and 
regenerative medicine are believed to harbour the great-
est potential and application field for the future, but un-
fortunately have recently experienced serious doubts and 
issues concerning safety, production and realization. The 
success of gene therapy is highly dependent on the qual-
ity of the delivery vector, which can be generally catego-
rized into viral and non-viral origin  [13] . Viral vectors are 
highly efficient. They are currently still the most power-
ful tools for gene transfection. However, some viral vec-
tors show limited loading capacity, are difficult to pro-
duce in large scale and, most importantly, pose severe 
safety risks due to their oncogenic potential and their in-
flammatory and immunogenic effects, which prevent 
them from repeated administration. To overcome these 
limitations, non-viral vectors have emerged as a promis-
ing alternative for gene delivery. A number of non-viral 
siRNA delivery approaches have now been reported in 
vivo, including in non-human primates and humans  [13–
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17] , among them hydrodynamic injection, cholesterol 
conjugation, cationic delivery systems such as liposomes 
and lipoplexes, as well as polymer- and peptide-based de-
livery systems, and other delivery routes, such as intra-
ocular delivery, intratumoral delivery, local in vivo elec-
troporation to muscle, local delivery to the central ner-
vous system and intranasal delivery to the airway  [18, 19] .
 Small chemicals (synthesized and natural molecules), 
in general, are easily produced in small and large scale by 
modern synthesis methods and can often be delivered
as a pill via the oral route into the circulation and gain 
access to the abnormal tissue (by diffusion) as well as to 
the cytoplasm of the target cell ( fig. 1 ). However, the past
two decades of enormous biotechnological expenditure 
worldwide with state-of-the-art high-throughput screen-
ing, structural biology, bioinformatics and rational drug 
design finally resulted in a rather disappointing outcome 
of approved small molecule drugs. This clearly demon-
strates the considerable difficulties inherent in the dis-
crimination of ‘chemicals’ and ‘drug-like’ molecules, that 
is, the selection from libraries containing millions of 
chemical substances those compounds with potential for 
subsequent successful step-by-step optimization via lead 
structures to drug candidates in course of several rounds 
of structural variation/modification with the help of ra-
tional design and structural biology. The reasons for 
these difficulties are complex and multi-facetted and not 
only based on scientific reasons. However, in any case, 
small chemicals intrinsically suffer from limited selectiv-
ity between the desired cellular target and unwanted off-
targets, which represent large macromolecules, such as 
proteins and nucleic acids. This selectivity issue is inti-
mately associated with safety problems and considerably 
impairs multi-parameter optimization. Therefore, it is 
not too surprising that during the past decade the identi-
fication of susceptibility genes for common diseases has 
over-run the introduction of novel small molecule drugs 
for their therapy, which target the corresponding gene 
products. This apparently huge problem with the identi-
fication of small drug molecules is in contrast to the need 
to obtain drugs for each defective/missing or hyperactive/
overproduced gene product encoded by the multiple sus-
ceptibility genes and underlying the common diseases.
 The gene products encoded by susceptibility genes are 
intrinsically characterized by exquisite potency and, in 
consequence, safety, in general, as well as by efficient qua-
si ‘inborn’ discovery ( fig. 1 ). Their wild-type versions rep-
resent ‘natural’ cell components. Therefore, upon their 
identification they may be used for therapy directly by 
substitution of defective or missing gene products or in-
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 Fig. 1. Current options for personalized prevention and therapy. 
Principal advantages and disadvantages of small drug molecules 
(chemicals), gene therapy (viral and non-viral vectors, non-vec-
tor-based vehicles), regenerative medicine (embryonic and adult 
stem cells, tissue engineering) and gene products (proteins and 
siRNA/microRNA encoded by susceptibility and disease genes) 
are given. Wild-type or appropriately modified versions of the lat-
ter can be used as therapeutic proteins which substitute for the 
missing or hypoactive gene products or for the generation of ther-
apeutic antibodies which inhibit the over-expressed or hyperac-
tive gene products. 
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directly by blockade of over-active or over-produced gene 
products using neutralizing antibodies directed against 
them. However, therapeutic proteins and antibodies have 
to overcome a number of critical hurdles prior to benefi-
cial systemic action. One of the most important is the 
passage along the gastrointestinal tract and the transport 
across intestinal epithelial cells into the circulation 
( fig. 2 ). For susceptibility gene products with major site of 
action in the serum (such as plasma enzymes) or intersti-
tial spaces (such as polypeptide hormones) this so-called 
oral bioavailability may represent the only barrier for tar-
geting their primary mode of action. Gene products with 
primary mode of action in the cytoplasm (such as tran-
scription factors, signalling proteins) have to be trans-
ported from the circulation via the extracellular matrix 
across the plasma membrane of the target tissue/cells, in 
addition ( fig. 2 ). This is typically not managed by thera-
peutic proteins and antibodies and therefore they have to 
be injected according to their site of action (that is, sub-
cutaneously, intravenously, intramuscularly or intraperi-
toneally).
 Consequently, personalized prevention and therapy 
based on the injection of gene products into the circula-
tion is per se prevented by their inability to be transport-
ed into the target cells or considerably limited by the 
known patient’s compliance toward their non-oral ad-
ministration. In particular, the latter holds true for com-
mon diseases, such as type II diabetes, which are often 
characterized during the initial stages by only low to 
moderate consequences for the individual life style and 
quality. However, many common diseases underlie vi-
cious cycles of their pathogenesis finally leading to irre-
versible damages, which resist improvement by late onset 
of non-oral administration of therapeutic proteins and 
antibodies. In former times, the emphasis of oral delivery 
of therapeutic proteins and antibodies was more on con-
venience and avoidance of needles. With the current un-
derstanding of the pathogenesis of multifactorial com-
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 Fig. 2. The intestinal permeability barrier. After ingestion and ar-
rival in the intestinal lumen the therapeutic protein or antibody 
has to pass the glycocalyx and mucus layers and then be trans-
ported into blood vessels and underlying tissue cells. Typically, 
proteins do not follow the transcellular route across the micro-
villi of the apical plasma membrane or the paracellular route 
across the protein complexes of tight junctions (oval). These con-
nect the neighbouring enterocytes to the intact and sealed intes-
tinal epithelial cell layer preventing macromolecules contained in 
the food from access to the circulation. The inset shows that dis-
tinct populations of enterocytes are arranged in the so-called 
brush border structures which line the intestinal wall with ab-
sorptive enterocytes located at the tip, stem cells located at the 
bottom in so-called crypts, proliferative precursor cells derived 
from the stem cells and enteroendocrine ‘Becher’ cells located be-
tween the tips and the crypts and engaged in the (glucose-depen-
dent) synthesis and release of neuroendocrine proteins, such as 
GLP-1, for the control of food intake and insulin release. 
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plex diseases, such as type II diabetes, additional empha-
sis has also been placed on the physiological importance 
of the most appropriate, that is natural, route of delivery 
of the protein therapeutic to its site(s) of action in the tar-
get tissues and cells. In case of therapy of type II diabetes 
this is the hepatic route  [20] . Existing insulin therapies 
including newer, injectable and short-acting analogues 
introduce insulin at the periphery and do not mimic
the normal, physiological portal-to-peripheral gradient. 
These therapies continue to over-insulinize the periph-
ery resulting in undesirable side effects, such as periph-
eral hyperinsulinemia with resulting insulin resistance, 
weight gain and hypoglycaemia. With hepatically deliv-
ered oral insulin there is the possibility of achieving high 
portal vein concentrations of insulin without sustained 
peripheral hyperinsulinemia. The physiological rational 
and therapeutic advantage for oral insulin has meanwhile 
been widely acknowledged by diabetologists  [20] . Taken 
together, the pathogenic mechanisms for common com-
plex diseases, which are based on multiple susceptibility 
genes, may be interrupted by substitution of the relevant 
gene products or introduction of the relevant neutraliz-
ing antibodies in the circulation and, if required, in the 
target cells in course of their oral delivery and, if required, 
subsequent transport across the plasma membrane ( fig.
1 ,  2 ).
 Transport across Intestinal Epithelial Cells 
 The greatest barriers to the oral delivery of therapeutic 
protein and antibodies lie in the gastrointestinal tract. 
Dietary proteins do not normally cross the gastrointesti-
nal epithelium intact, but must first be broken down to 
their constituent free amino acids and peptides by vari-
ous enzymes located throughout the gastrointestinal 
tract. These constituents are then absorbed by the gastro-
intestinal epithelium. Of course, this route of protein ab-
sorption destroys almost all physiological activity of the 
original protein or polypeptide and explains why typical 
oral bioavailabilities of proteins are usually less than 
1–2%  [21] . Therefore, despite the fact that recombinant 
DNA technology has allowed for ever increasing num-
bers of therapeutic proteins and antibodies, delivery of 
these drugs is still generally through injection. For the 
past 8 decades, a great deal of work has focused on at-
tempts to develop non-invasive methods of delivering 
protein drugs with the oral route clearly being the most 
convenient and desired one.
 The earliest attempts for oral delivery of a protein ther-
apeutic date back to the 1930s and were devoted to short-
acting insulin formulations. These studies were per-
formed to understand if insulin could be adsorbed via the 
portal vein by directly injecting insulin into the intestinal 
loop  [22] . In fact, 30 years later it was demonstrated that 
there may be some, albeit very limited, ability for proteins 
to cross the intestinal epithelium intact if administered 
directly in the intestinal lumen thus avoiding the acidic 
environment of the stomach  [23] . In another study, a hex-
ylresorcinol solution containing insulin was adminis-
tered to 10 healthy volunteers. The study successfully 
showed a reduction in blood glucose levels, but concluded 
that oral delivery of insulin exhibits great interindividual 
variability and poor bioavailability  [24] . According to 
these early studies  [22–24] , some proteins and peptides, 
most often lipophilic ones, have actually been shown to 
have useful oral bioavailabilities. Insulin, unfortunately, 
does not and is effectively stopped by the natural barriers 
to protein delivery. Overcoming these barriers is the fo-
cus of efforts to develop oral delivery systems for thera-
peutic proteins and antibodies, in general, and insulin, in 
particular.
 Which are the main reasons for the failure of proteins 
to become transported after their oral ingestion from the 
intestinal lumen into the blood vessels, the interstitial 
spaces surrounding the target tissues and the cytoplasm 
of the target cells? The epithelial layer lining the gastro-
intestinal tract is a tightly bound collection of cells with 
minimal leakage and forms a physical barrier to absorp-
tion ( fig. 2 ). It is made up of a single layer of columnar 
epithelial cells supported by the lamina propria and mus-
cularis mucosa. The epithelium folds to form villi (the 
brush border) and each epithelial cell also possesses mi-
crovilli, uniform one-micrometer finger-like projections, 
on its apical surface. Together, these structures increase 
the absorptive area of the intestinal tract by approximate-
ly two orders of magnitude  [25] . However, these struc-
tures hinder the absorption of proteins as the microvilli 
also contain digestive enzymes. In addition to these for-
midable barriers, on top of the epithelial layer lies the gly-
cocalyx, a layer of sulphated mucopolysaccharides, and a 
layer of mucus consisting of glycoproteins, enzymes, elec-
trolytes and water. Glycocalyx and mucus present yet an-
other physical barrier to the transport of proteins.
 Neighbouring epithelial and endothelial cells are 
tightly bound to one another by specific protein complex-
es, the so-called tight junctions of zona occludens, which 
ensure their assembly into stably sealed tissues. Proteins 
in the circulation or in the interstitial space are usually 
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prevented from ‘transcellular’ passage across the apical 
plasma membrane via the cytoplasm to and across the 
basolateral plasma membrane as well as from ‘paracellu-
lar’ passage between the basolateral plasma membranes 
of neighbouring epithelial and endothelial cell layers via 
the tight junctions ( fig. 2 ). The size and hydrophilic na-
ture of typical serum proteins (and thus putative protein 
therapeutics), such as enzymes, hormones, growth fac-
tors or antibodies, are not compatible with their passive 
or facilitated diffusion across plasma membranes or tight 
junctions. Furthermore, apparently there was no evolu-
tionary pressure for the development of specific active 
and receptor-mediated mechanisms for the transport of 
proteins from the intestinal lumen into the circulation, 
whereas those have evolved for the transport of hormones 
and growth factors from the circulation into the target 
tissues.
 In addition to the physical barrier provided by the in-
testinal epithelium, proteins face another, possibly great-
er, barrier in the form of digestive enzymes acting along 
the gastrointestinal tract. Protein digestion by proteases 
starts in the stomach and is continued by many different 
enzymes located throughout the intestinal tract  [26] . 
Pepsins are located in the stomach and trypsin, chymo-
trypsin and carboxypeptidases released from the pancre-
as are located in the small intestinal lumen  [27] . These 
pancreatic enzymes are responsible for only about 20% of 
enzymatic degradation of ingested proteins. The remain-
der of the degradation occurs at the brush-border mem-
brane or in the cytosol of enterocytes of the intestinal 
tract by various peptidases, among them the so-called 
insulin-degrading enzyme  [28] . Many attempts have 
been made to overcome these enzymatic barriers (see be-
low). But this is certainly a difficult challenge since the 
presence of just one or two of these enzymes could lead 
to total denaturation or destruction of a protein drug.
 The final major barrier to the development of effective 
oral protein delivery systems rests in the actual fabrica-
tion methods for the formulation to be used. Unlike low 
molecular weight drugs, proteins have a complex internal 
structure which helps define their biological activity. Any 
alteration in the primary (amino acid sequence), second-
ary (two-dimensional structure), tertiary (folding) or 
quaternary structure (combination of polypeptide sub-
units) can result in the deactivation of a protein. These 
alterations may be caused by even the slightest changes in 
the environment (or even microenvironment) of the pro-
tein. The most likely variables which can affect protein 
structure and stability are related to the temperature, pH, 
solvent, ingredients and crystallinity states of the protein. 
These considerations are most pertinent when using 
polymer-encapsulated formulations. Many of the basic 
encapsulation methods used in the production of poly-
mer-based protein drug delivery systems can easily dis-
rupt the delicate protein structure rendering the protein 
inactive. Therefore, although the characterization of the 
releasing kinetics of therapeutic proteins and antibodies 
from putative drug delivery systems is important, under-
standing the stability of the protein is just as critical. This 
topic should not be neglected when discussing barriers to 
oral protein delivery  [25, 29] . Despite these apparent chal-
lenges, there have been intensive efforts of pharmacolo-
gist and biotechnologists during the past decades to en-
able or improve the oral bioavailability of therapeutic 
proteins and antibodies for the chronic therapy of com-
mon diseases, such as cancer, cardiovascular diseases and 
metabolic diseases, including type II diabetes, on the ba-
sis of a variety of distinct and sophisticated technologies, 
which are mentioned here only in brief ( fig. 3 ).
 General Approaches for the Oral Delivery of Protein 
Therapeutics 
 Bypassing of the intestinal epithelial transport barrier 
has been tackled by several approaches  [30, 31] . (1) The 
most common strategy which has been followed is encap-
sulation of the protein drug in liposomes and micro- or 
nanoparticles. Nanoparticle formulations using muco-
adhesive polymers, such as chitosan, poly(lactic-)co-gly-
colic acid, poly-  -glutamic acid and alginate, poly(alkyl-)
cyanoacrylate microparticles and   -cyclodextrin lipo-
somes have been studied extensively  [32–37] . The protein 
drugs encapsulated in these polymers are apparently 
physically protected from enzymatic degradation and it 
has been shown clearly that such particles cross the epi-
thelial layer through Peyer’s patches  [38] . While some of 
the encapsulated protein drugs have been demonstrated 
to exert the desired physiological effect in appropriate an-
imal models, such as lowering of blood glucose in strep-
tozotocin-diabetic rats in the case of insulin, further de-
velopment has not been reported. Presumably, the nano-
materials, which are currently in use, ‘actively’ induce the 
transient opening of the tight junctions in course of their 
direct binding to protein components of the zona oc-
cludens and thereby enable the paracellular passage of the 
encapsulated therapeutic proteins into the circulation. 
One critical disadvantage of this ‘site-specific’ delivery 
and ‘colonic absorption’ could be the inability to ade-
quately correct and compensate for all physiological as-
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pects of the missing or defective endogenous gene prod-
uct, such as the loss of first-phase insulin secretion in
the case of insulin.
 (2) The prevention of the enzymatic degradation in the 
gastrointestinal tract in course of delivery of the protein 
drug along with a protease inhibitor could represent a 
useful strategy, too. In one pilot study, 5 different protease 
inhibitors were tested individually along with insulin 
 [39] . It was found that bacitracin, sodium glycocholate 
and camostat mesilate promoted the absorption of insu-
lin, while soya bean trypsin inhibitor has very little effect 
on the absorption. The study concluded that co-admin-
istration of protease inhibitors is one possible approach 
to improve the absorption of protein drugs, such as insu-
lin, from the gastrointestinal tract  [39] , presumably due 
to prolonged survival period of the intact protein drug at 
the intestinal epithelium which raises the probability of 
its absorption. A general limitation of this approach is 
that the long-term effect of chronic administration of 
protease inhibitors is unknown and may result in protein 
malabsorption and other adverse side effects. This may 
be one reason why this approach has not reached clinical 
trials so far for the most attractive candidates for oral 
protein delivery in the long term, such as insulin. Alter-
natively, derivatization of polypeptide drugs by using 
polyethylene glycol  [40] and their encapsulation in pH-
responsive gels and films  [41] or in enteric-coated cap-
sules containing sodium salicylate  [42] , which become 
gradually dissolved or leaky along passage in the gastro-
intestinal tract, have been reported to prevent their enzy-
matic degradation and to enhance their absorption  [43] . 
A number of these promising approaches have been tak-
en into the clinics.
 (3) Several permeation enhancers have been analysed 
for their capability to increase the efficacy of oral protein 
delivery. The most commonly tried permeation enhanc-
ers are bile salts or fatty acids for increasing the permea-
bility across the intestinal cell walls, presumably via the 
transcellular route. Salts of fatty acids like caprate, capry-
late, laurate or palmitate have been tested for oral delivery 
of insulin, other peptides and certain macromolecules 
with variable success  [44, 45] . The co-administration of 
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other penetration enhancers based on detergent-like 
molecules and micelles, such as pluronic acid  [46] , seems 
to destabilize or weaken the tight junctions facilitating 
the paracellular routing of protein drugs  [47] . Moreover, 
a specific toxin, zonula occludens toxin, is currently be-
ing assessed as permeation enhancer for insulin and has 
been demonstrated to be effective in reducing blood glu-
cose levels in animal models of diabetes  [48] . In fact, this 
toxin apparently opens up the tight junctions in effective 
and reversible fashion and thereby manages to improve 
the permeability of protein drugs, such as insulin. How-
ever, these permeation enhancers could potentially dam-
age or even dissolve the gastrointestinal barrier and 
thereby facilitate the access of undesired small and large 
compounds from the intestinal lumen into the circula-
tion with increased risks for local inflammations and 
gastrointestinal infections. Furthermore, prior to routine 
therapeutic application, the unspecific oral delivery of 
proteins and protein fragments originating from the food 
as an unwanted consequence of the general loss of the 
permeability barrier and protective function formed by 
the enterocytes has to be excluded for each type and each 
combination of penetration enhancers. Thus, long-term 
toxicity of this approach needs to be evaluated on a case-
by-case basis. Considering the intrinsic specificity issue 
of this ‘general permeation enhancer’ approach and the 
challenging task to prove its safety in the long term, the 
encapsulation of the therapeutic proteins and antibodies 
into nanoparticles seems to be more promising ( fig.  3 ) 
 [49, 50] . Taken together, multiple approaches for oral pro-
tein delivery have been tested so far and offered early 
promise, but very few of them have made it beyond pre-
clinical stages.
 From the Circulation to Target Tissues and into 
Target Cells 
 Irrespective of the strategy used to overcome the bar-
rier of the gastrointestinal tract (see above), after success-
ful para- or transcellular passage of the therapeutic pro-
teins and antibodies across the intestinal epithelial cells, 
they only manage to act extracellularly in the circulation 
(for example by inhibition of serum enzymes, such as en-
dothelial lipase) in case of neutralizing antibodies or in 
the interstitial tissue spaces or at the surface of the target 
cells (for example by activation of cell surface receptors, 
such as the insulin receptor) in case of hormones and 
growth factors ( fig. 3 ). The penetration of the ‘nude’ ther-
apeutic protein or antibody into the target cell to gain ac-
cess to the cytoplasm and relevant organelles, for example 
the nucleus, is typically extremely inefficient due to the 
permeability barrier formed by the plasma membranes 
for large hydrophilic macromolecules. This represents a 
general and serious limitation for the use of protein ther-
apeutics. Thus, the development of safe and effective 
drug carriers that can be orally administered but will se-
lectively deliver therapeutic protein drugs into the dis-
eased cells without harming normal cells is an additional 
and essential goal of nanomedicine  [51, 52] .
 Interestingly, the size of the nanoparticles and the 
thickness and type of the nanomaterials used apparently 
determines the systemic trafficking of the nanocarriers 
in the circulation following their transit across the intes-
tinal barrier ( fig. 3 ; thick or thin continuous or interrupt-
ed envelopes). This could open the possibility for specific 
targeting of therapeutic proteins and antibodies to the af-
fected tissues, such as muscle, fat, liver and pancreas for 
type II diabetes therapy or to proliferating malignant 
cells for cancer therapy. The strategy of ‘passive targeting’ 
relies on the relatively selective extravasation and reten-
tion of long-circulating nanocarriers on the basis of spe-
cific structural features of the diseased tissue. The strat-
egy of ‘active targeting’ is based on the modification of 
the surface of nanosized carriers with ligands that can 
specifically recognize the diseased cells. These two clini-
cally relevant and nanocarrier-based targeting strategies 
rely on the specific interaction between the ligands (anti-
bodies, peptide mimics or nucleic acids) on the carrier 
surface and the corresponding receptors expressed on the 
diseased cells. For example, human epidermal growth 
factor receptor-2  [53–55] , folic acid receptor  [46] and va-
soactive intestinal peptide receptors  [56] have been inves-
tigated as biomarkers for nanocarriers targeted to breast 
tumours. Recently, new targeting strategies have emerged 
as a way of improving the targeting efficiency of the 
nanocarriers. They are based on the unique microenvi-
ronment of surrounding tumour cells (‘tumoral extracel-
lular environment’) as a molecular cue to activate long-
circulating nanocarriers to release the drug or facilitate 
their cellular uptake upon arrival at the target tumour 
sites.
 Many different macromolecular structures, such as 
drug-polymer conjugates, micelles, liposomes, dendri-
mers and nanoparticles, have been designed to transport 
drugs to their intended target tissues and cells. Micelles 
can be made from amphiphilic block co-polymers that 
self-assembly into small spherical structures  [47, 57] . Li-
posomes are vesicles made of phospholipid bilayers that 
can encapsulate drugs in their luminal cores or interfaces 
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between the bilayers  [57] . Nanoparticles are generally 
polymeric matrices in the form of nanosized colloids that 
can encapsulate a drug through physical entrapment (as-
sociation between the drug and polymer) or chemical 
conjugation (creating a chemical bond between the drug 
and polymer)  [49, 50] .
 Some of the recently reported targeting strategies have 
good potential to achieve both passive and active target-
ing effects. These strategies aim to create nanocarriers 
that maintain the stealth property during circulation 
(passive targeting) and then transform to more cell-inter-
active form (active targeting) upon arrival at the target 
sites on the basis of the unique extracellular environment 
of the diseased cells. For instance, tumours develop 
unique microenvironments, such as slightly acidic pH 
 [58] and a high level of proteinases  [59] . The extracellular 
pH of malignant tissues is generally more acidic (pH 6.5–
7.2) due to the increased glycolysis of tumour cells, which 
makes them produce more lactic acid and release it into 
the surrounding milieu than normal cells  [60, 61] . The 
overproduction of enzymes, such as the matrix metallo-
proteinases, is also common for most proliferating malig-
nant cells, since they are essential for angiogenesis, me-
tastasis, and other extracellular signalling events in-
volved in tumour propagation  [59] . Overexpression of 
metalloproteinases has been explored as a way of target-
ing and ‘turning on’ of imaging agents for the allocation 
of tumours or other lesions  [62–64] .
 However, for chronic therapeutic application of 
nanoparticles, the possibility and extent of their system-
ic entry has to be investigated, including the relevant de-
grading and eliminating pathways. In case of oral deliv-
ery of therapeutic proteins and antibodies, solely, their 
systemic entry is unwanted but often unavoidable, 
whereas in case of systemic tissue targeting, this is even 
required. Most importantly, the accumulation of the 
nanomaterials in tissues and cells, which either harbour 
the target of the orally delivered therapeutic protein (and 
nanoparticles) or serve as unspecific sink for the 
nanoparticles after their systemic distribution in the 
whole body, has to be excluded in the long term. Very 
recent experimental results hint to the exciting possibil-
ity that a novel strategy for both oral delivery and tissue 
targeting in parallel will overcome these potential toxic-
ity issues. It is based on a ‘natural’ co-translational mod-
ification of the therapeutic protein with a glycolipid 
structure, the covalent coupling to glycosylphosphati-
dylinositol (GPI).
 GPI Proteins – Structure and Synthesis 
 GPI represents a typical glycolipidic structure consist-
ing of phosphatidylinositol with long-chain saturated fat-
ty acids which is coupled via a complex glycan core, a 
terminal phosphoethanolamine bridge and an amide 
linkage to the carboxy terminus of a subset of (often gly-
cosylated) membrane proteins ( fig. 4 )  [65–68] . Thereby, 
these GPI-anchored proteins (GPI proteins) are anchored 
at the surface of eucaryotic cells from yeast to man  [69, 
70] . Typical transmembrane proteins cross the phospho-
lipid bilayer of biological membranes via one or several 
stretches of 12–20 hydrophobic amino acids each, which 
in combination act(s) as membrane anchor(s) ( fig. 4 )  [71, 
72] . In contrast, the GPI anchor is inserted in the outer 
(extracellular) phospholipid monoleaflet of the plasma 
membrane, exclusively, with preference for special areas, 
so-called lipid rafts or detergent-insoluble glycolipid-en-
riched microdomains (DIGs). DIGs are characterized by 
high concentrations of cholesterol, glycolipids, glyco-
sphingolipids and phospholipids harbouring long-chain 
fatty acids  [73–78] . The resulting rigid lipid environment 
attracts subsets of transmembrane proteins, such as the 
caveolins, and the majority of GPI proteins. DIGs formed 
by the typical membrane phospholipids and proteins 
float like rafts in the ocean. They have been attributed a 
multitude of important cellular functions, such as trans-
port of cholesterol, fatty acids and proteins as well as sig-
nal transduction across the plasma membrane  [79, 80] . 
The GPI anchor is susceptible to cleavage by special types 
of serum phospholipases C or D  [81–84] . They operate in 
constitutive or regulated fashion during a number of 
physiological (for example insulin action  [85] ) and phar-
macological (for example glimepiride action  [86, 87] ) 
processes or are used for the experimental release of the 
(hydrophilic) protein moiety from the membrane or cell 
surface for the diagnosis of GPI anchorage ( fig. 4 )  [88] .
 The co-translational coupling of the GPI anchor to the 
protein moiety during the biosynthesis of GPI proteins 
requires the presence of two distinct targeting signals, 
signal sequences I and II, which flank the GPI protein 
precursor encoded by the relevant susceptibility gene 
( fig. 5 ). Signal sequence I at the amino terminus, which is 
structurally and functionally identical to that operating 
for the transport in secretory and transmembrane pro-
teins, directs the (still GPI anchor-less) nascent polypep-
tide chain of the GPI protein for co-translational transfer 
across the membrane of the endoplasmic reticulum. Sig-
nal sequence II at the carboxy terminus, which structur-
ally resembles a proteinaceous transmembrane anchor, 
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dictates the transient ‘stop transfer’ of the nascent poly-
peptide chain. Thereafter, signal sequence II becomes re-
placed by the GPI anchor (prefabricated at the endoplas-
mic reticulum membrane by sequential glycosylation of 
phosphatidylinositol) in the course of a specific transam-
idation reaction. Subsequently, the completed GPI pro-
tein with its GPI anchor embedded in the luminal leaflet 
of the endoplasmic reticulum membrane is transported 
along the secretory pathway. Upon final fusion of the se-
cretory vesicles with the plasma membrane the GPI pro-
tein moiety becomes exposed at the cell surface with the 
GPI anchor being inserted into the extracellular mem-
brane leaflet of the DIGs ( fig. 5 ). Meanwhile, the biosyn-
thesis of this complex co-translational modification, in-
cluding all genes which code for the glycosylation en-
zymes and the transamidase, has been unravelled  [68–70, 
89] and found to be highly conserved from yeast to man. 
Of critical importance for the use of GPI proteins in ther-
apy is the possibility to convert (almost) each (soluble) 
protein (of potential therapeutic interest) into its GPI-an-
chored version  [90] . For this, its gene sequence simply has 
to be coupled to the signal sequences I and II by recom-
binant DNA manipulation. The biochemical analyses of 
a number of recombinant fusion proteins with hydro-
philic polypeptide domains coupled at their carboxy ter-
minus to GPI anchors of varying fatty acid composition 
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 Fig. 4. Structures of two common classes of eucaryotic plasma 
membrane proteins. Typical transmembrane proteins span the 
phospholipid bilayer of the plasma membrane with one to several 
  -helical stretches of 12–20 hydrophobic amino acids each (in 
brown, colour only in online version), thereby directing one to 
several hydrophilic polypeptide domains to the cell surface (often 
with disulfide bridges and carbohydrate chains) and to the cyto-
plasm (always reduced and unglycosylated). The atypical trans-
membrane protein, caveolin-1, does not span the phospholipid 
bilayer, but penetrates only into the cytoplasmic leaflet of the plas-
ma membrane with a hook-like hydrophobic segment thereby di-
recting both the terminal small and large polypeptide domains to 
the cytoplasm. Caveolin-1 is predominantly enriched at the DIGs 
(see text for details). GPI proteins are anchored in the outer leaflet 
of the plasma membrane by the GPI glycolipid structure. GPI is 
built up of phosphoethanolamine, a glycan core consisting of sev-
eral mannose and non-acetylated glucosamine residues in typical 
glycosidic linkages,  myo -inositol (Ino) and phosphatidic acid 
equipped with saturated long-chain fatty acids. The GPI anchor 
is amide-linked to the carboxy terminus of the hydrophilic poly-
peptide moiety located at the cell surface. Putative cleavages by 
the (G)PI-specific phospholipases C and D expressed at the plas-
ma membrane of (rat) adipocytes and in (human) serum which 
result in the generation of diacylglycerol and phosphatidic acid, 
respectively, and the release of the polypeptide moiety with gly-
can-phosphate and glycan remnants, respectively. 
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in comparison to those with proteinaceous transmem-
brane anchors revealed only no to moderate effects of the 
GPI anchor on the enzymic, binding or signalling func-
tions of the corresponding passenger proteins  [91–95] . 
This might have been unexpected given the previously ob-
served very close proximity of the protein moiety of GPI 
proteins to the membrane surface  [96] . The apparent func-
tional independence of the passenger protein and GPI an-
chor will facilitate the versatile construction of appropri-
ate therapeutic GPI protein/antibody fusion polypeptides.
 Upon transfection of yeast, insect or appropriately cul-
tured mammalian cells with the corresponding viral or 
plasmid vectors, GPI-anchored fusion proteins will be ex-
pressed in high amounts and with considerable enrich-
ment  [90] and can be used after preparation of total intact 
or detergent-solubilized cellular membranes or after their 
(partial) purification and subsequent reconstitution into 
liposomes. Moreover, the recombinant ectopic GPI pro-
teins or GPI antibodies can be selectively extracted from 
the cell surface of the mammalian or yeast host cells by 
specific non-ionic detergents, such as   -amidotaurocho-
late  [97, 98] , and be reconstituted into detergent micelles 
without the need for further purification to homogeneity 
( fig. 5 ). Complexes of GPI fusion proteins and detergents 
may potentially be used for oral delivery and subsequent 
transport of therapeutic proteins and antibodies into or 
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 Fig. 5. Biosynthesis and recombinant expression of GPI proteins 
in eucaryotic cells. The gene encoding the (eventually modified) 
therapeutic protein or antibody passenger is fused (by recombi-
nant DNA technology) at its 5  -end to the signal sequence I in-
cluding the start codon and the cleavage site for the signal pepti-
dase (orange scissors, colour only in online version) and at its 3  -
end to the signal sequence II, which consists of a hydrophobic 
transiently membrane-spanning segment (light green) including 
the transamidase (blue scissors) recognition site   and a hydro-
philic segment (dark green) including the stop codon. Signal se-
quences I and II derived from typical secretory proteins and GPI 
proteins, respectively, are inserted as cassettes into appropriate 
shuttle vectors (virus or plasmid based) for efficient transfection 
of yeast (for example  Saccharomyces cerevisiae ) or mammalian 
cells (for example CHO, COS, HEK293). Trancription of the pas-
senger sequences is controlled by the upstream located strong 
(and possibly regulated) promoter in concert with the down-
stream located terminator, translation by the upstream located 
5  -untranslated region (5  -UTR) in concert with the downstream 
located 3  -untranslated region (3  -UTR). Upon co-translational 
transport into the endoplasmic reticulum, cleavage of signal se-
quence I by signal peptidase and cleavage of signal sequence II 
under concomitant coupling of the passenger protein precursor 
to the pre-fabricated GPI anchor (P = phosphate, G = glycan, I = 
inositol, C-C = ethanolamine) by transamidase, the GPI protein 
is delivered to the plasma membrane by vesicular transport 
through the cytoplasm and finally inserted into DIGs with the 
passenger protein moiety facing the cell surface. For therapeutic 
applications the GPI protein can be extracted from plasma mem-
brane DIGs with non-ionic detergents and reconstituted into de-
tergent micelles using routine procedures. 
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across enterocytes, into the circulation, certain target tis-
sues and the cytoplasm of certain target cells ( fig. 3 ).
 Trafficking of GPI Proteins in Adipocytes 
 The following recent experimental findings raised by 
several research laboratories for a variety of cell types dif-
ferent from enterocytes suggest the potential of GPI mod-
ification of therapeutic proteins for their oral delivery 
and, if required, for their subsequent translocation into 
the cytoplasm of the target tissue cells ( fig. 3 ). Recombi-
nant purified GPI proteins, reconstituted into detergent 
micelles, spontaneously associate with (target) cells of 
different origin upon incubation in vitro ( fig. 6 )  [99–107] . 
The GPI anchor inserted into the outer leaflet of the DIGs 
plasma membrane mediates anchorage and presentation 
of the (passenger) protein at the cell surface  [99, 107–109] . 
This so-called ‘cell surface painting’ has already been 
used for the ectopic expression of modified antigens (for 
immunization), receptors (for signal transmission) or 
binding proteins (for transport) at the cell surface of bio-
technologically relevant mammalian cells, which does 
not rely on (sometimes troublesome) DNA transfection 
methods  [101, 110] . Importantly, the newly acquired cell 
surface proteins may undergo transcytosis, that is trans-
cellular transport via the cytoplasm from the apical to the 
basolateral plasma membrane, in polarized cells or trans-
location across the plasma membrane into the cytoplasm 
of both polarized and non-polarized cells ( fig. 3 ). It is well 
established that DIGs, which per se appear as ‘flat’ struc-
tures, can form invaginations oriented toward the cyto-
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 Fig. 6. Model for the transfer of GPI proteins into DIGs and ca-
veolae. Step A: GPI proteins or antibodies reconstituted into de-
tergent micelles and exposed to intact mammalian cells sponta-
neously insert into the outer (extracellular) leaflet of plasma 
membrane areas deprived of endogenous GPI proteins, glycolip-
ids and cholesterol (non-DIG areas). Step B: GPI proteins/anti-
bodies (but not transmembrane proteins) undergo time-depen-
dent lateral movement into DIGs enriched in endogenous GPI 
proteins, glycolipids and cholesterol. Step C: caveolin-1, synthe-
sized as soluble protein in the cytosol, becomes incorporated into 
the inner (cytoplasmic) leaflet of the DIGs plasma membrane, 
which is fostered by its affinity to cholesterol. The subsequent 
oligomerization of the caveolin-cholesterol complexes drives the 
formation of cave-like invaginations at the DIGs along with the 
GPI proteins/antibodies and glycolipids at the outer leaflet and a 
subset of transmembrane proteins which all reside at the DIGs. 
Completion of the invagination and budding leads to the genera-
tion of closed caveolin-coated vesicles, so-called caveolae, with 
the GPI anchors embedded in luminal leaflet of the caveolar 
membrane and the GPI protein/antibody moieties facing the ca-
veolar lumen. The underlying molecular mechanism resembles, 
but is not identical with, endocytosis of non-clathrin-coated ves-
icles. 
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plasm. Upon synthesis of the atypical transmembrane 
protein, caveolin-1, its post-translational insertion into 
and both homo- and heterooligomerisation and complex 
formation with cholesterol within the cytoplasmic leaflet 
of the DIGs membrane bilayer  [111–115] trigger the bud-
ding of closed vesicles, so-called caveolae, from the plas-
ma membrane into the cytoplasm ( fig. 6 ).
 Transcytosis of GPI proteins in polarized cells (for ex-
ample endothelial cells, enterocytes, epithelial cells) and 
their reported preferential targeting to either the apical or 
basolateral plasma membranes  [116–118] may be medi-
ated by caveolae harbouring the GPI proteins at their lu-
minal face in the course of their partial or complete non-
clathrin- but caveolin-mediated endocytosis  [119–121] . 
The underlying molecular mechanisms may encompass 
the lateral diffusion of the GPI proteins along the luminal 
leaflets of tubular membrane structures formed by the 
fused caveolae  [122] . These could transverse the cyto-
plasm and connect the apical and basolateral plasma 
membranes. Alternatively, distinct non-fusing caveolar 
vesicles may carry the luminal GPI protein across the cy-
toplasm from the extracellular leaflet of the apical plasma 
membrane to that of the basolateral plasma membrane 
upon their budding and fusion, respectively  [115, 123, 
124] . With both mechanisms the transcellular transport 
of GPI proteins will result in their anchorage at the sur-
face (in DIGs) of the basolateral membrane of enterocytes 
or endothelial cells oriented towards their underlying in-
terstitial tissue spaces.
 The previously demonstrated translocation of GPI 
proteins from plasma membrane DIGs into the cyto-
plasm of non-polarized cells, such as adipocytes, occurs 
constitutively, but at a low rate, and becomes significant-
ly up-regulated in response to physiological (such as pal-
mitate, H 2 O 2 ) or pharmacological (such as anti-diabetic 
sulfonylurea glimepiride) stimuli ( fig.  7 ; step A)  [125–
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 Fig. 7. Model for the intra- and intercellular trafficking of GPI 
proteins within adipose tissue. Step A: GPI proteins or antibodies 
enriched at plasma membrane DIGs of adipocytes are translo-
cated to the surface of LD via embedding of their GPI anchors in 
the LD phospholipid monolayer. Step B: subsequently, they be-
come associated with adiposomes, presumably emerging at plas-
ma membrane DIGs (light brown lines, colour only in online ver-
sion), via embedding of their GPI anchors in the outer leaflet of 
the adiposome phospholipid bilayer. Step C: the adiposomes har-
bouring the GPI proteins are released from the (preferably large) 
donor adipocytes. Step D: the adiposomes circulate within the 
same or between distinct adipose tissue depots and come into 
contact with plasma membrane DIGs of (preferably small) accep-
tor adipocytes. Step E: this triggers the transfer of the GPI protein 
cargo of the adiposomes to the DIGs via embedding of their GPI 
anchors in the outer leaflet of the DIGs phospholipid bilayer. Step 
F: subsequent translocation of the GPI proteins and antibodies to 
the surface of LD via embedding of their GPI anchors in the LD 
phospholipid monolayer leads to cytoplasmic orientation of their 
catalytic and antigen-binding protein moieties, respectively. 
Translocation of the GPI proteins from DIGs to LD in both donor 
and acceptor adipocytes (steps A and F) as well as the release of 
the adiposomes (step B) are positively controlled by certain exog-
enous physiological (palmitate, H 2 O 2 ) and pharmacological 
(glimepiride) signals. 
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127] . In the course of translocation, GPI proteins previ-
ously residing at plasma membrane DIGs or caveolae of 
adipocytes appear in highly enriched fashion at the sur-
face of cytoplasmic lipid droplets (LD)  [128, 129] . LD act 
as the storage organelles for triacylglycerols, which rep-
resent hydrophobic, highly reduced and concentrated 
carriers of energy  [130–132] . Thus, energy storage is 
compartmentalized in LD in eucaryotic cells, in general. 
In adipocytes, the most highly specialized cells dedicat-
ed to store energy, LD often occupy the bulk of the cyto-
plasm. In mammals, energy storage and catabolism in 
LD is highly regulated by the nutritional state and hor-
mones via engagement of downstream signalling path-
ways. The triacylglycerols are deposited together with 
cholesterylesters in the core of the LD, which is sur-
rounded by a phospholipid monolayer with intercalated 
free fatty acids as well as cholesterol and decorated with 
specific proteins, such as perilipin-A  [130–132] . In addi-
tion to compartmentalized energy storage, LD are in-
volved in intracellular protein storage and metabolism. 
For instance, during development of the fruit fly  Dro-
sophila,  histones accumulate at the surface of LD until 
their successful import and complexing to DNA in rap-
idly dividing nuclei  [133] . During replication of the hep-
atitis C virus in infected humans, its core protein also 
localizes to LD in hepatocytes  [134, 135] . LD also has 
been linked functionally to the spliceosome and protea-
some  [132, 133, 136, 137] . Thus, LD might serve as plat-
forms for the coordination and regulation of deposition 
and degradation of various types of proteins, among 
them membrane proteins, nuclear proteins and soluble 
proteins of both endogenous and exogenous origin, in 
addition to mere energy storage.
 Very recently, two GPI proteins, Gce1 and CD73, have 
been found associated with LD of rat adipocytes. They 
are anchored at the LD surface through insertion of their 
GPI fatty acyl chains into the LD phospholipid mono-
layer and expose their protein moiety toward the cyto-
plasm ( fig. 7 ; step A) [128, 129] . The molecular mecha-
nisms responsible for this atypical topological reorienta-
tion of GPI proteins from the extracellular/luminal to the 
cytoplasmic localization (which apparently does not fit 
the rules of vectorial vesicular transport along the classi-
cal secretory pathway) remain to be elucidated. They may 
be based on a novel specialized type of endocytosis with 
subsequent vesicular trafficking to the endoplasmic re-
ticulum where the de novo biogenesis of LD with accom-
panying assembly of the reoriented GPI proteins at the 
cytoplasmic face of the endoplasmic reticulum mem-
brane takes place ( fig. 8 ). Alternatively, the involvement 
of micellar or bicellar structures which are formed with-
in the DIGs and consist of GPI proteins, phospholipids, 
glycolipids and additional proteins (for example those 
destined for removal and degradation during quality 
control)  [138] is conceivable ( fig. 8 ). These structures may 
represent primordial LD prior to their filling with triac-
ylglycerol and cholesterylester.
 Trafficking of GPI Proteins between Adipocytes 
 Unexpectedly, in rat adipocytes LD-associated Gce1 
and CD73 were found to be redirected from the LD to 
small vesicles, so-called adiposomes, and thereby to be re-
leased into the incubation medium during pulse-chase ex-
periments ( fig. 7 ; step B)  [127] . The GPI anchor of Gce1 
and CD73 becomes embedded in the extracellular leaflet 
of the adiposomal phospholipid bilayer and the protein 
moieties exposed at the adiposomal surface  [139, 140] . 
These adiposomes resemble the well-characterized mi-
crovesicles and exosomes harbouring subsets of trans-
membrane  [141–143] and GPI proteins  [82, 139, 144] , 
which are released from most mammalian cells into the 
circulation in vivo or into the incubation medium in vitro. 
The release of microvesicles following plasma membrane 
blebbing or shedding as well as of exosomes following 
plasma membrane fusion, that is exocytosis, of so-called 
multivesicular bodies, which both presumably occur at 
plasma membrane DIGs  [142–156] , is either constitutive 
 [145] or upregulated by cellular activation or apoptosis 
 [146–148] . In general, microvesicles and exosomes are as-
sumed to operate as vehicles for the transfer of informa-
tion-carrying proteins, among them GPI proteins, from 
donor to acceptor cells. Thereby, information is trans-
ferred in horizontal fashion which may be related to a 
multitude of physiological and pathophysiological func-
tions, such as apoptosis induction, correction of parox-
ysmal nocturnal haemoglobinuria, control of blood co-
agulation and platelet activation, propagation of prion 
protein or tumour metastasis  [145–169] . Similarly, adipo-
somes in concert with the surface-exposed GPI proteins 
are released from (preferably large) donor adipocytes in 
moderate and constitutive and, more potently, regulated 
fashion (by the same signals which elicit the translocation 
of GPI proteins from the cell surface to the LD surface, see 
above) ( fig. 7 ; step C) and become associated (in spontane-
ous and constitutive fashion) with plasma membrane 
DIGs of (preferably small) acceptor adipocytes ( fig. 7 ; step 
D)  [139, 140] . Subsequently, the GPI proteins are trans-
ferred from these bound adiposomes to DIGs during a 
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spontaneous and constitutive process that depends on the 
integrity of both the GPI anchors and the DIGs and re-
mains restricted to subsets of transmembrane proteins 
and GPI proteins ( fig. 7 ; step E). Thereafter, the transferred 
GPI proteins are translocated in the absence or, more po-
tently, presence of exogenous signals (palmitate, glimepiri-
de, H 2 O 2 ) from the plasma membrane DIGs to the intra-
cellular LD of the acceptor adipocytes ( fig. 7 ; step F). This 
translocation of exogenous GPI proteins seemingly paral-
lels that of their endogenous GPI protein counterparts and 
finally leads to GPI anchorage at the surface monolayer of 
LD with the protein moieties facing the cytoplasm.
 This complex inter- and intracellular trafficking of 
GPI proteins has recently been demonstrated for the ad-
iposome-mediated transfer of the GPI-anchored (c)AMP-
degrading enzymes, Gce1 and CD73, from donor to ac-
ceptor adipocytes and their subsequent translocation to 
cytoplasmic LD of the acceptor adipocytes  [170–172] . The 
expression of Gce1 and CD73 at the LD surface with their 
(c)AMP-degrading catalytic domains gaining access to 
the cytoplasm leads to lowering of the concentration of 
(c)AMP at the LD surface zone ( fig.  9 ). The resulting 
blockade of cAMP-dependent phosphorylation causes 
the inhibition of hormone-sensitive lipase and activation 
of glycerol-3-phosphate acyltransferase in the immediate 
vicinity of the LD  [170–172] . Thus, this mechanism coor-
dinates down-regulation of lipolysis and up-regulation of 
esterification which both ultimately foster triacylglycerol 
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 Fig. 8. Three putative mechanisms for the intracellular trafficking 
of GPI proteins from DIGs to LD. In the model of micellar traf-
ficking, micelles consisting of phospholipids, caveolin-1 and the 
GPI proteins are formed at the DIGs (light brown, colour only in 
online version) of the plasma membrane (dark brown), which 
then escape from the DIGs, move through the cytoplasm and fi-
nally deliver their cargo GPI protein to the LD, possibly by spon-
taneous insertion into their phospholipid monolayer (orange). In 
the model of vesicular trafficking, GPI proteins in concert with 
caveolin-1 are internalized by (non-clathrin-coated) endocytic 
vesicles forming at the DIGs with their protein moieties (red) fac-
ing the vesicle lumen. During subsequent movement of the endo-
cytic vesicles through the cytoplasm and their fusion with the 
endoplasmic reticulum, reorientation of the GPI proteins by a 
‘flip-flop’ mechanism leads to inversed topology with their pro-
tein moieties facing the cytoplasm and their GPI anchors embed-
ded in the cytoplasmic leaflet of the endoplasmic reticulum bi-
layer. The de novo biogenesis of LD at these sites of the endoplas-
mic reticulum with budding of the cytoplasmic membrane leaflet 
will drive the integration of typical LD-associated proteins, such 
as perilipin and caveolin-1, as well as of the atypical LD-associat-
ed GPI proteins into the phospholipid monolayer surrounding the 
nascent LD. These increase in size and grow to mature LD by the 
synthesis and incorporation of triacylglycerol and cholesteryles-
ters into the LD core (orange). In the model of bicellar trafficking, 
small phospholipid micelles harbouring GPI proteins and caveo-
lin-1, so-called bicelles, are transiently formed at DIGs leaving 
‘plasma membrane holes’ with sealing ‘phospholipid edges’. Sub-
sequently, the bicelles are released from the DIGs into the cyto-
plasm under concomitant closure of the ‘plasma membrane holes’ 
and then sequentially converted into nascent and mature LD as 
described for the vesicular trafficking model. Irrespective of the 
molecular mechanism, the trafficking has been demonstrated to 
operate constitutively at low rate, but to be significantly up-regu-
lated by exogenous physiological (for example palmitate, H 2 O 2 ) 
and pharmacological (for example glimepiride) signals. 
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synthesis and LD biogenesis. As a consequence, informa-
tion about (c)AMP-dependent signalling and metabolic 
pathways, such as the stimulation of esterification and 
inhibition of lipolysis, is transmitted between physiolog-
ically distinct (large and small) adipocyte subpopulations 
within the same (for example subcutaneous) tissue depot 
(that is, in paracrine fashion) or between different (for 
example subcutaneous and visceral) depots (that is, in en-
docrine fashion). Thus, in adipose tissue communication 
via adiposomes seems to signal the shift of burden of lip-
id loading from large ‘old’ to small ‘young’ adipocytes 
( fig. 7 ) and may trigger LD biogenesis and differentiation 
of pre-adipocytes  [5, 170] . 
 DIGs and LD as Common Denominators between 
Adipocytes and Enterocytes 
 More than 95% of dietary fat consumed is absorbed 
whether a low- or high-fat diet is consumed  [173] , as evi-
denced by the small amount of fat that is excreted in fae-
ces in either case. In the small intestine lumen, dietary fat 
in the form of triacylglycerol is hydrolyzed to generate 
free fatty acids and monoacylglycerol by pancreatic li-
pase. These cleavage products are then emulsified with 
the help of phospholipids and bile acids present in bile to 
form micelles. Both free fatty acids and monoacylglyc-
erol are then taken up by the absorptive cells of the small 
intestine, the enterocytes, where they are re-synthesized 
into triacylglycerol and incorporated into the core of chy-
lomicrons which are secreted via the lymphatic system 
into the circulation  [174, 175] . Surprisingly, wild-type 
mice fed a high-fat diet or challenged with an oil bolus by 
oral gavage are commonly reported as having no LD ac-
cumulation in enterocytes  [176–178] . Nevertheless, both 
indirect and direct evidence exists supporting the pres-
ence of a cytoplasmic triacylglycerol storage pool in en-
terocytes. In humans, sequential meal tests demonstrated 
that chylomicrons secreted after a second meal carried 
triacylglycerol ingested during the first meal  [179, 180] . 
In rats, triacylglycerol is synthesized within 30 s after an 
intraduodenal fat infusion  [181] . However, the secretion 
of triacylglycerol into the lymph does not reach a steady 
state until 4 h after infusion, suggesting that the rate-lim-
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Fig. 9. Model for the involvement of intra-adipocyte trafficking of 
the GPI proteins, Gce1 and CD73, for the regulation of lipid me-
tabolism. -Adrenergic challenge of adipocytes with isoprotere-
nol increases total cytoplasmic cAMP leading to stimulation of 
lipolysis, the release of fatty acids from triacylglycerol, and inhibi-
tion of esterification, the incorporation of fatty acids into triacyl-
glycerol. Exogenous signals, such as palmitate, glimepiride and 
H2O2, promote the translocation of Gce1 and CD73 from plasma 
membrane DIGs (light brown lines, colour only in online version) 
to LD. The resulting cAMP-to-adenosine conversion and lower-
ing of the cAMP levels at the LD surface zone by the concerted 
actions of the cAMP-specific phosphodiesterase activity of Gce1 
and 5-nucleotidase activity of CD73 cause inhibition of lipolysis 
and stimulation of esterification with concomitant upregulation 
of LD biogenesis and adipocyte differentiation.
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iting step in dietary fat absorption is the transport of tri-
acylglycerol from the endoplasmic reticulum to the Golgi 
apparatus  [182] . This led the investigators to hypothesize 
that during this period, triacylglycerol resides on the cy-
toplasmic leaflet of the endoplasmic reticulum mem-
brane for later secretion  [183] . In addition, more triacyl-
glycerol was found in the cytoplasm of enterocytes pre-
pared from high fat-fed compared to chow-fed rabbits by 
biochemical analysis  [184] . Finally, electron microscopy 
images of enterocytes from humans challenged with fat 
loads demonstrated the existence of a cytoplasmic triac-
ylglycerol storage pool  [185] . Re-synthesized triacylglyc-
erol, which first enters a cytoplasmic storage pool, may 
not be immediately available for the synthesis of chylomi-
crons. However, upon lipolysis and re-esterification it 
may then enter the lumen of the endoplasmic reticulum 
where the assembly of chylomicrons begins. Neverthe-
less, whether a dynamic cytoplasmic pool of triacylglyc-
erol and, in consequence, LD exists during the process of 
dietary fat absorption has remained controversial so far 
 [186] .
 However, very recently the presence of LD in entero-
cytes has been demonstrated on the basis of resonant co-
herent anti-Stokes Raman scattering microscopy signals 
from symmetric CH 2 stretch vibration  [187] . The nature 
of the LD was confirmed by biochemical analysis to pre-
dominantly consist of triacylglycerol. Combined coher-
ent anti-Stokes Raman scattering microscopy and fluo-
rescence imaging showed that these LD were located in 
the cytoplasm and coated with the LD-specific PAT pro-
tein TIP47  [188] . The amount of triacylglycerol stored in 
the enterocytes was found to be highly dependent on the 
region of the intestine and directly correlated with the 
amount of fat consumed. Moreover, the recent observa-
tions of LD in ex vivo fresh intestinal tissues provided 
direct evidence that dietary free fatty acids enter a dy-
namic cytoplasmic triacylglycerol pool in enterocytes in 
response to a dietary fat challenge  [187] . Together the re-
sults highlight the dynamics of the cytoplasmic triacyl-
glycerol pool in enterocytes which may have evolved to 
insure the absorption of highly energy-dense macronutri-
ents during times when food was scarce  [187] . Mamma-
lian enterocytes are constantly renewing and turn over 
every 3–4 days. Thus, mammalian enterocytes would not 
be considered a long-term storage depot for triacylglyc-
erol, as mammals have adipose tissue to serve this pur-
pose. Nonetheless, the temporal storage of triacylglycerol 
in enterocytes allows its excess after a meal rich in dietary 
lipid to be conserved within the cell as opposed to being 
excreted in faeces. The storage of triacylglycerol in LD of 
enterocytes after a meal rich in dietary fat may also allevi-
ate lipotoxicity to enterocytes by high concentration of 
free fatty acids  [189] . Based on these data, a revised model 
of triacylglycerol metabolism within enterocytes has been 
proposed to depict the physiological role of LD in entero-
cytes during dietary fat absorption. This model is consis-
tent with previous models describing triacylglycerol stor-
age and secretion in hepatocytes and enterocytes  [186] . In 
this model diacylglycerol is synthesized from the products 
of dietary fat digestion, monoacylglycerol and fatty acyl-
coenzyme A. Triacylglycerol is then synthesized from di-
acylglycerol and fatty acyl-coenzyme A. In enterocytes 
the synthesized triacylglycerol has 2 potential fates: direct 
incorporation into nascent chylomicrons for immediate 
secretion via the Golgi apparatus or storage in cytoplas-
mic LD. It should be noted that the existence of a cytoplas-
mic triacylglycerol pool has been well accepted for hepa-
tocytes where triacylglycerol is recycled and secreted in 
the form of very low-density lipoprotein  [186, 190] .
 Hypothetical Model for Trafficking of GPI Proteins 
across Enterocytes 
 Albeit experimental data are lacking so far, entero-
cytes may behave similar to adipocytes with regard to 
inter- and intracellular trafficking of GPI proteins. This 
assumption seems to rely on a sound basis given the 
known high contents of plasma membrane DIGs  [191, 
192] and LD  [187] in rodent enterocytes. Consequently in 
analogy to adipocytes, for enterocytes the following 
multi-step model for the oral delivery of therapeutic pro-
teins and antibodies in the course of transcellular trans-
port and/or translocation onto the surface of cytoplasmic 
LD and subsequent release via microvesicles/exosomes 
and translocation into the cytoplasm of acceptor cells can 
be envisaged. It is based on the unique property of GPI 
proteins to associate through their GPI anchor with de-
tergent micelles, plasma membrane DIGs, LD and mi-
crovesicles/exosomes in a fashion compatible with inter- 
and intracellular trafficking as well as physiological func-
tion ( fig. 3 ).
 Step 1: following oral ingestion of pH-sensitive film- 
or gel-coated microspheres (for protection against low pH 
and proteases/glucosidases in the stomach, see above) en-
capsulating appropriately formulated mixed micelles of 
detergent and the therapeutic GPI fusion proteins/anti-
bodies of interest, the GPI protein load will be released in 
the intestinal lumen. Thereafter, the GPI proteins will 
spontaneously insert into DIGs of the apical plasma 
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membrane of intestinal enterocytes. Step 2: the GPI pro-
teins are translocated from the DIGs to the surface of cy-
toplasmic LD of the enterocytes. Step 3: the GPI proteins 
are then translocated from the LD to DIGs of the basolat-
eral plasma membrane or, alternatively, to multivesicular 
endosomal bodies for initiation of the biogenesis of mi-
crovesicles and exosomes, respectively. Both transloca-
tion steps are stimulated by exogenous signals, such as 
palmitate, glimepiride or H 2 O 2 . In case of missing trans-
location of the GPI proteins to microvesicles/exosomes, 
they will remain associated at the LD surface and may 
fulfil (the desired) physiological (for example enzymic or 
neutralizing) function directed toward a cytosolic target 
or mechanism. Step 4: upon completion of shedding
of the microvesicles or exocytosis of the multivesicular 
bodies from the basolateral plasma membrane, the vesi-
cle-associated GPI fusion proteins/antibodies become 
distributed via the circulation. Step 5: in case of the ther-
apeutic protein/antibody exerting an extracellular func-
tion in the circulation (for example as enzyme or neutral-
izing antibody) or in the interstitial spaces of the target 
tissue (for example as ligand for cell surface receptors), its 
release from the circulating microvesicles/exosomes may 
or may not be necessary (depending on the protein’s na-
ture, such as size, surface charge, steric hindrance by 
GPI) to ensure access to interacting proteins, co-factors 
or substrates in the blood or to allow free diffusion and 
transport to the relevant extracellular matrix. GPI an-
chors are cleaved specifically by (G)PI-specific phospho-
lipases ( fig.  4 ), among them serum phospholipase D, 
which may provoke lipolytic release of therapeutic pro-
teins/antibodies from GPI anchorage at circulating mi-
crovesicles/exosomes. Phospholipase D is highly ex-
pressed in human serum  [82, 84] , albeit its efficacy to-
ward GPI anchors embedded in intact membranes of 
microvesicles/exosomes remains to be clarified  [193, 194] . 
Nevertheless, human GPI-specific phospholipase D rep-
resents a candidate enzyme for the last step in the trans-
cellular transport of a therapeutic GPI fusion protein/an-
tibody from the intestinal lumen into the circulation and 
its conversion from the amphiphilic into its hydrophilic 
version. Step 6: in case of the therapeutic protein/anti-
body exerting a function in the cytoplasm of the target 
tissue cells (for example as signalling protein or neutral-
izing antibody), the lipolytic release has to be reduced or 
completely prevented. This could be achieved by alter-
ation of the putative cleavage site for the GPI-specific 
phospholipase D within the GPI anchor by site-directed 
mutagenesis of glycosylation enzymes involved in the 
biosynthesis of the GPI glycan core at the endoplasmic 
reticulum in the recombinant host cells used for the GPI 
protein production ( fig. 5 ).
 The model proposed for the intracellular and intercel-
lular transport of GPI proteins across enterocytes and 
from enterocytes to target tissue cells, respectively, is cur-
rently based on findings obtained with adipocytes, exclu-
sively, and is therefore of hypothetical nature. However, 
its relevance for the oral delivery of therapeutic proteins/
antibodies and their subsequent targeting to the plasma 
or to the cytoplasm of tissue cells can now be studied in 
vitro and in vivo. Appropriate test models include the 
passage of GPI fusion proteins (preferably equipped with 
easily measurable reporter enzymes) from the apically to 
the basolaterally oriented incubation medium of cultured 
intestinal epithelial cells and the systemic delivery of GPI 
hormones (such as GPI insulin) upon their oral adminis-
tration to appropriate animal models of the disease (such 
as diabetic rodents) and analysis of the corresponding 
physiological effect (such as blood glucose decrease).
 Trafficking of GPI Proteins beyond Enterocytes and 
Adipocytes 
 The recently reported observations with adipocytes 
 [171, 172] raised the possibility for the operation of similar 
mechanisms of inter- and intracellular trafficking of GPI 
proteins between and in other tissue cells, such as pancre-
atic   , muscle or liver cells, with their transfer from mi-
crovesicles/exosomes to plasma membrane DIGs and sub-
sequent translocation to the surface of cytoplasmic LD. 
Both DIGs and LD are present in virtually all mammalian 
cell types studied so far, albeit at considerably varying 
amounts  [73–79, 130–132, 195, 196] . The subcellular loca-
tion at the LD surface enables the therapeutic protein/an-
tibody to substitute for missing or subnormal activity or 
to dampen hyperactivity of a gene product encoded by a 
polymorphic/mutant susceptibility gene ( fig.  1 ). More-
over, during the past few years LD have been recognized 
as a complex, well-organized and dynamic organelle ex-
erting a multitude of important and heterogenous func-
tions (see above) rather than being a simple and static lip-
id-filled balloon with mere storage capabilities for fatty 
acids and cholesterol in both adipose and non-adipose 
cells ( fig. 10 )  [133] . The apparent role of LD in the specific 
retention and release of regulatory and structural pro-
teins, such as those involved in the intracellular replica-
tion of several infectious agents, including  Chlamydia and 
hepatitis C virus  [134, 137] , suggests new therapeutic op-
tions for a variety of common diseases, including infec-
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tions. Consequently, this enlarged ‘portfolio’ of LD could 
make themselves and the molecular mechanisms under-
lying their biogenesis, in general, as well as the inter- and 
intracellular trafficking of GPI proteins to LD, in particu-
lar, attractive as drug targets for therapeutic proteins and 
antibodies with regard to a variety of common complex 
diseases ( fig. 11 ). In addition to infection and metabolic 
disorders, such as obesity and type II diabetes, the candi-
dates for potential future therapies with LD-targeted GPI 
proteins and antibodies encompass cardiovascular dis-
eases, cancer, Alzheimer’s disease and aging.
 Most important for future progress will be the ‘proof 
of this concept’ with intestinal epithelial cells, in general, 
and with relevant target tissue cells, in particular, includ-
ing the demonstration of its superior efficacy compared 
to non-oral and alternative oral (and so far only experi-
mentally used) application routes. Moreover, a number of 
potential safety issues have to be addressed adequately. 
Among them is the potential immunogenicity caused by 
single or few carbohydrate, phosphate or amino acid res-
idues left at the carboxy terminus of the released thera-
peutic protein/antibody upon cleavage of its GPI anchor 
by serum phospholipases, phosphodiesterases, glucosi-
dases or proteases. Moreover, in vivo the time course of 
cleavage and release from microvesicles/exosomes of the 
therapeutic GPI proteins/antibodies may critically affect 
the onset and duration of their physiological actions.
 In general, for oral delivery of protein therapeutics to 
become reality for patients suffering from chronic dis-
eases, such as type II diabetes, there are a number of im-
portant challenges that need to be addressed irrespective 
of the technology applied  [197–200] . First, long-term ef-
ficacy and safety need to be demonstrated through ade-
quately powered studies in different patient populations 
across the spectrum of the disease. Reproducible absorp-
tion of the protein drug and understanding of meal-relat-
ed absorption are clearly important goals for developing 
a drug that needs to be administered life-long. Second, 
clinical studies need to demonstrate superiority over in-
jectable regimens of the protein drug as well as over oral-
ly available small-molecule drugs. As an example, for oral 
insulin the therapeutic goals are improved hypoglycae-
mic profile, reduced weight gain and, in general, better 
disease progression outcome in long-term studies in 
comparison to short-acting injectable human insulin and 
metformin pills. Third, one of the important open points 
of long-term protein delivery through the oral route is its 
potential for inducing mitogenic changes in the gut mu-
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Fig. 10. Multiple functions of LD. LD are heavily engaged in the 
regulated uptake, esterification and lipolytic release of fatty acids 
and cholesterol for a multitude of both endogenous and exoge-
nous uses, which are predominantly related to the compartmen-
talization of both energy and building blocks for the biosynthesis 
of membranes and signalling molecules, in a variety of adipose 
and non-adipose cells. In addition, LD seem to fulfil important 
roles in the storage and controlled release of proteins.
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cosa. For instance, insulin as being an, albeit mild, growth 
promoter has always been under scrutiny for this poten-
tial toxicity issue. This would need to be addressed in 
long-term toxicity studies. Fourth, the success of oral 
protein drug delivery depends on the ability to manufac-
ture the (for example GPI-modified) protein both in suf-
ficient quantities for oral delivery as well as efficiently in 
a cost-conscious pharmaceutical marketplace. If all these 
issues are successfully addressed, a treatment paradigm-
changing therapy of chronic diseases with oral delivery 
of protein drugs may be the result.
 Conclusions 
 Taken together, the technology of glycolipid-based, 
that is GPI-modified, therapeutic proteins/antibodies in 
combination with special formulations, such as pH-sen-
sitive gels, detergent micelles and nanoparticles, could 
enable the efficient oral delivery of protein drugs and 
their targeting to the sites of action of the corresponding 
abnormal gene products encoded by polymorphic/mu-
tant susceptibility genes. No doubt, overcoming the 
known hurdles will be challenging, but this is presum-
ably a prerequisite for achieving the goal of personalized 
prevention and therapy of multifactorial complex com-
mon diseases in the medium term. Ideally, they will en-
compass patient-tailored combinations of GPI proteins/
antibodies which address as many as feasible of the prod-
ucts affected by the susceptibility genes in a tissue-spe-
cific fashion. GPI proteins and antibodies may thus in-
crease the number of druggable targets, which so far re-
sist attack by small molecules, as well as the number of 
drugs, which exhibit exquisite specificity toward their 
target.
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Fig. 11. LD as putative drug targets. During the past decade, LD 
have been recognized as intracellular organelles fulfilling multi-
ple functions in the storage, chaperoning and degradation of mac-
romolecules. Among them are regulatory and vesicular traffick-
ing proteins controlling the storage, scavening and detoxification 
of lipophilic (toxic) substances, the retention, release and move-
ment of organelles, the subcellular compartmentalization and the 
cell surface exposure as well as release into microvesicles and exo-
somes of metabolic enzymes and signalling proteins, such as the 
GPI proteins, Gce1 and CD73, in both adipose and non-adipose 
cells. The biogenesis of the LD with concomitant upregulation of 
esterification and downregulation of lipolysis and, in conse-
quence, the LD-mediated physiological functions, such as the re-
lease of proteins into microvesicles and exosomes, are controlled 
by expression of the relevant proteins at the LD, such as the GPI 
proteins Gce1 and CD73. Vice versa, the LD expression of proteins 
is affected by the LD biogenesis. In adipose cells, the role of LD 
has been clearly established for the pathogenesis of certain com-
mon complex diseases, such as obesity and type II diabetes. In 
non-adipose cells novel functions have been suggested for LD, 
such as during tumorigenesis and aging, but have to be confirmed 
by rigorous experimentation for the validation of LD as future 
drug target.
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Müller
 
Pharmacology 2010;86:92–116 112
 1 Prokopenko I, McCarthy MJ, Lindgren CM: 
Type 2 diabetes: new genes, new understand-
ing. Trends Genet 2008; 24: 613–621. 
 2 Ridderstrale M, Groop L: Genetic dissection 
of type 2 diabetes. Mol Cell Endocrinol 2009; 
 297: 10–17. 
 3 Lindgren CM: Mechanisms of disease: ge-
netic insights into the etiology of type 2 dia-
betes and obesity. Nat Clin Pract 2007; 4: 156–
163. 
 4 Florez JC: The genetics of type 2 diabetes: a 
realistic appraisal in 2008. J Clin Endocrinol 
Metab 2008; 93: 4633–4642. 
 5 Müller G: Personalized prognosis and diag-
nosis of type II diabetes – vision or fiction? 
Pharmacology 2010; 85: 168–187. 
 6 Lusis AJ, Attie AD, Reue K: Metabolic syn-
drome: from epidemiology to systems biol-
ogy. Nature Genet 2008; 9: 819–830. 
 7 Gibson G: Decanalization and the origin of 
complex disease. Nature 2009; 10: 134–140. 
 8 Janssens ACJW, van Duijn CM: Genome-
based prediction of common diseases: ad-
vances and prospects. Hum Mol Genet 2008; 
 17:R166–R173. 
 9 McCarthy MI, Smedley D, Hide W: New 
methods for finding disease-susceptibility 
genes: impact and potential. Genome Biol 
2003; 4: 119. 
 10 Rothman KJ, Greenland S: Causation and 
causal interference in epidemiology. Am J 
Pub Health 2005; 95(suppl 1):S144–S150. 
 11 Edwards KL, Hutter CM, Wan JY, Kim H, 
Monks SA: Genome-wide linkage scan for 
the metabolic syndrome: The GENNID 
study. Obesity 2008; 16: 1596–1601. 
 12 Janssens ACJW, Pardo MC, Steyerberg EW, 
van Dujin CM: Revisiting the clinical valid-
ity of multiplex genetic testing in complex 
diseases. Am J Hum Genet 2004; 74: 585–588. 
 13 Li SD, Huang L: Non-viral is superior to viral 
gene delivery. J Controlled Release 2007; 123: 
 181–183. 
 14 Xie FY, Woodle MC, Lu PY: Harnessing in 
vivo siRNA delivery for drug discovery and 
therapeutic development. Drug Discovery 
Today 2006; 11: 67–73. 
 15 Martin SE, Caplen NJ: Development of new 
RNAi therapeutics. Histol Histopathol 2007; 
 22: 211–217. 
 16 Leung RK, Whittaker PA: RNA interference: 
from gene silencing to gene-specific thera-
peutics. Pharmacol Ther 2005; 107: 222–239. 
 17 Kim DH, Rossi JJ: Strategies for silencing hu-
man disease using RNA interference. Nat 
Rev Genet 2007; 8: 173–184. 
 18 Suda T, Suda K, Liu D: Computer-assisted 
hydrodynamic gene delivery. Mol Ther 2008; 
 16: 1098–1104. 
 19 Gao K, Huang L: Nonviral methods for
siRNA delivery. Mol Pharmaceut 2009; 6: 
 651–658. 
 20 Arbit E: The physiological rationale for oral 
insulin administration. Diabetes Technol 
Ther 2004; 6: 510–517. 
 References 
 21 Lasch F, Schönbrunner E: Weitere Untersu-
chungen über die enterale Insulinresorp-
tion, über den Schutz des Insulins gegen 
Trypsin. Naunyn Schmiedeberg Arch Phar-
macol 1936; 182: 452–458. 
 22 Young LE, Phillips WA, Murlin JR: New re-
sults on the absorption of insulin from the 
alimentary tract. Am J Physiol 1939; 128: 81–
91. 
 23 Pauletti G, Gangwar S, Knipp GT, Nerurkar 
MM, Okuma FW, Tamura K, Siahaan TJ, 
Borchardt RT: Structural requirements for 
intestinal absorption of peptide drugs. J 
Control Release 1996; 41: 3–17. 
 24 Moriya H, Moriwaki C, Akimote S, Yamagu-
chi K, Iwadareet M: Studies on the passage of 
alpha-chymotrypsin across the intestine. 
Chem Pharm Bull 1967; 15: 1662–1668. 
 25 Wang W: Oral protein drug delivery. J Drug 
Target 1996; 4: 195–232. 
 26 Woodley JF: Enzymatic barriers for GI pep-
tide and protein delivery. Crit Rev Ther Drug 
Carrier Syst 1994; 11: 61–95. 
 27 Guyton AC: Digestion and absorption in the 
gastrointestinal tract; gastrointestinal disor-
ders; in Human Physiology and Mechanisms 
of Disease, ed 5. Philadelphia, WB Saunders, 
1992, pp 500–509. 
 28 Bai JPF, Chang LL: Transepithelial transport 
of insulin. I. Insulin degradation by insulin-
degrading enzyme in small intestinal epithe-
lium. Pharm Res 1995; 12: 1171–1175. 
 29 Schwendeman SP, Cardamone M, Klibanov 
A, Langer R: Stability of proteins and their 
delivery from biodegradable polymer micro-
spheres; in Cohen S, Bernstein H (eds): Mi-
croparticulate Systems for the Delivery of 
Proteins and Vaccines. New York, Marcel 
Dekker, 1996, pp 1–49. 
 30 Ziv E, Lior O, Kidron M: Absorption of pro-
tein via the intestinal wall. Biochem Pharm 
1987; 36: 1035–1039. 
 31 Carino PC, Mathiowitz E: Oral insulin deliv-
ery. Adv Drug Deliv Rev 1999; 35: 249–257. 
 32 Aspden TJ, Mason JD, Jones NS: Chitosan as 
a nasal delivery system: the effect of chitosan 
solutions on in vitro and in vivo mucocilliary 
transport rates in human turbinates and vol-
unteers. J Pharm Sci 1997; 86: 509–513. 
 33 Mathiowitz E, Jacob JS, Jong YS, Carino GP, 
Chickering DE, Chaturvedi P, Santos CA, 
Vijayaraghavan K, Montgomery S, Bassett 
M, Morrell C: Biologically erodible micro-
spheres as potential oral drug delivery sys-
tems. Nature 1997; 386: 410–414. 
 34 Damge C, Michael C, Aprahamian M, Cou-
vreur P: New approach for oral administra-
tion of insulin with polyalkylcyanoacry-
latenanocapsules as oral carrier. Diabetes 
1988; 37: 247–251. 
 35 Takka S, Acarturk F: Calcium alginate mi-
croparticles for oral administration. I. Effect 
of sodium alginate type on drug release and 
drug entrapment efficiency. J Microencapsul 
1999; 16: 275–290. 
 36 Rowsen ML, Dileep KJ, Sharma CP:   cyclo-
dextrin-insulin-encapsulated chitosan/algi-
nate matrix: oral delivery system. J Appl 
Polym Sci 2000; 75: 1089–1096. 
 37 Dapergolas G, Gregoriadis G: Hypoglycae-
mic effect of liposome-entrapped insulin ad-
ministered intragastrically into rats. Lancet 
1976; 2: 824–827. 
 38 Pappo J, Ermak TH: Uptake and transloca-
tion of f luorescent latex particles by rabbit 
Peyer’s patch follicle epithelium: a quantita-
tive model for M cell uptake. Clin Exp Im-
munol 1989; 76: 144–148. 
 39 Yamamoto A, Taniguchi T, Rikyuu K, Tsuji 
T, Fujita T, Murakami M, Muranishi S: Ef-
fects of various protease inhibitors on the in-
testinal absorption and degradation of insu-
lin in rats. Pharm Res 1994; 11: 1496–1500. 
 40 Abuchowski A, McCoy JR, Palczuk NC, van 
Es T, Davis FF: Effect of covalent attachment 
of polyethylene glycol on immunogenicity 
and circulating life of bovine liver catalase. J 
Biol Chem 1977; 252: 3582–3586. 
 41 Lowman AM, Morishita M, Kajita M, Nagai 
T, Peppas NA: Oral delivery of insulin using 
pH-responsive complexation gels. Int J 
Pharm 1999; 88: 933–937. 
 42 Hosny EA, Al-Shora HI, Elmazar MMA: 
Oral delivery of insulin from enteric-coated 
capsules containing sodium salicylate: effect 
on relative hypoglycaemia of diabetic beagle 
dogs. Int J Pharm 2002; 237: 71–76. 
 43 Clement S, Still JG, Kosutic G, McAllister 
RG: Oral insulin product hexyl-insulin 
monoconjugate 2 (HIM2) in type 1 diabetes 
mellitus: the glucose stabilization effects of 
HIM2. Diabetes Technol Ther 2002; 4: 459–
466. 
 44 Palin KJ, Philipps AJ, Ning A: The oral ab-
sorption of cefoxitin from oil and emulsion 
vesicles in rats. Int J Pharm 1986; 33: 99–104. 
 45 Mesiha M, Plakogiannis F, Vejosoth S: En-
hanced oral absorption of insulin from de-
solvated fatty acid-sodium glycocholate 
emulsions. Int J Pharm 1994; 111: 213–216. 
 46 Wang YZ, Yu L, Han L, Sha XY, Fang XL: 
Difunctional pluronic copolymer micelles 
for paclitaxel delivery: synergistic effect of 
folate-mediated targeting and Pluronic-me-
diated overcoming multidrug resistance in 
tumor cell lines. Int J Pharm 2007; 337: 63–73. 
 47 Matsumara Y: Polymeric micellar delivery 
systems in oncology. Jpn J Clin Oncology 
2008; 38: 793–802. 
 48 Fasano A, Uzzau S: Modulation of intestinal 
tight junctions zona occludens toxin permits 
enteral administration of insulin and other 
macromolecules in an animal model. J Clin 
Invest 1997; 99: 1158–1164. 
 49 Uhrich KE, Cannizzaro SM, Langer RS, 
Shakesheff KM: Polymeric systems for con-
trolled drug release. Chem Rev 1999; 99: 
 3181–3198. 
 Transport of Glycolipid-Modified 
Proteins: Vision or Fiction? 
Pharmacology 2010;86:92–116 113
 50 Soussan E, Cassel S, Blanzat M, Rico-Lattes 
I: Drug delivery by soft matter: matrix and 
vesicular carriers. Angew Chem Int Ed 2009; 
 48: 274–288. 
 51 Ebbesen M, Jensen TG: Nanomedicine: tech-
niques, potentials, and ethical implications. 
J Biomed Biotechnol 2006, DOI 10.1155/
JBB/2006/51516. 
 52 Gullotti E, Yeo Y: Extracellularly activated 
nanocarriers: a new paradigm of tumor tar-
geted drug delivery. Mol Pharmaceut 2009; 6: 
 1041–1051. 
 53 Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, 
Shim CK, Kim DD: Preparation and evalua-
tion of paclitaxel-loaded PEGylated immu-
noliposome. J Controlled Release 2007; 120: 
 169–177. 
 54 Kirpotin DB, Drummond DC; Shao Y, Sha-
laby MR, Hong KL, Nielsen UB, Marks JD, 
Benz CC, Park JW: Antibody targeting of 
long-circulating lipidic nanoparticles does 
not increase tumor localization but does in-
crease internalization in animal models. 
Cancer Res 2006; 66: 6732–6740. 
 55 Mamot C, Drummond DC, Noble CO, Kal-
lab V, Guo ZX, Hong KL, Kirpotin DB, Park 
JW: Epidermal growth factor receptor-tar-
geted immunoliposomes significantly en-
hance the efficacy of multiple anticancer 
drugs in vivo. Cancer Res 2005; 65: 11631–
11638. 
 56 Dagar S, Krishnadas A, Rubinstein I, Blend 
MJ, Onyuksel H: VIP grafted sterically sta-
bilized liposomes for targeted imaging of 
breast cancer: in vivo studies. J Controlled 
Release 2003; 91: 123–133. 
 57 Yokoyama M: Drug targeting with nano-
sized carrier systems. J Artif Organs 2005; 8: 
 77–84. 
 58 Gerweck LE, Seetharaman K: Cellular pH 
gradient in tumor versus normal tissue: Po-
tential exploitation for the treatment of can-
cer. Cancer Res 1996; 56: 1194–1198. 
 59 Egeblad M, Werb Z: New functions for the 
matrix metalloproteinases in cancer pro-
gression. Nat Rev Cancer 2002; 2: 161–174. 
 60 Montcourrier P, Silver I, Farnoud R, Bird I, 
Rochefort H: Breast cancer cells have a high 
capacity to acidify extracellular milieu by a 
dual mechanism. Clin Exp Metastasis 1997; 
 15: 382–392. 
 61 Swallow CJ, Grinstein S, Rotstein OD: A vas-
cuolar type H(+)-ATPase regulates cytoplas-
mic pH in murine macrophages. J Biol Chem 
1990; 265: 7645–7654. 
 62 Mok H, Bae KH, Ahn C-H, Park
TG: PEGylated and MMP-2 specifically
dePEGylated quantum dots: comparative 
evaluation of cellular uptake. Langmuir 
2009; 25: 1645–1650. 
 63 Scherer RL, VanSaun MN, McIntyre JO, Ma-
trisian LM: Optical imaging of matrix me-
talloproteinase-7 activity in vivo using a pro-
teolytic nanobeacon. Mol Imaging 2008; 7: 
 118–131. 
 64 Weissleder R, Tung CH, Mahmood U, Bog-
danov A: In vivo imaging of tumors with 
protease-activated near-infrared fluorescent 
probes. Nat Biotechnol 1999; 17: 375–378. 
 65 Nosjean O, Briolay A, Roux B: Mammalian 
GPI proteins: sorting, membrane residence 
and functions. Biochim Biophys Acta 1997; 
 1331: 153–186. 
 66 Brewis IA, Ferguson MAJ, Mehlert A, Tur ner 
AJ, Hooper NM: Structures of the glycosyl-
phosphatidylinositol anchors of porcine and 
human erythrocyte renal membrane dipep-
tidase. Comprehensive structural studies on 
the porcine anchor and interspecies compar-
ison of the glycan core structures. J Biol 
Chem 1995; 270: 22946–22956. 
 67 Ikezawa H: Glyosylphosphatidylinositol 
(GPI)-anchored proteins. Biol Pharm Bull 
2002; 25: 409–417. 
 68 Englund PT: The structure and biosynthesis 
of glycosyl phosphatidylinositol protein an-
chors. Annu Rev Biochem 1993; 62: 121–139. 
 69 Tiede A, Bastisch I, Schubert J, Orlean P, 
Schmidt RE: Biosynthesis of glycosylphos-
phatidylinositols in mammals and unicellu-
lar microbes. Biol Chem 1999; 380: 503–523. 
 70 Orlean P, Menon AK: Thematic review se-
ries: lipid posttranslational modifications. 
GPI anchoring of protein in yeast and mam-
malian cells, or: how we learned to stop wor-
rying and love glycophospholipids. J Lipid 
Res 2007; 48: 993–1011. 
 71 Singer SJ, Nicolson GL: The fluid mosaic 
model of the structure of cell membranes. 
Science 1972; 175: 720–728. 
 72 Jacobson K, Sheets ED, Simson R: Revisiting 
the fluid mosaic model of membranes. Sci-
ence 1995; 268: 1441–1446. 
 73 Brown D, London L: Functions of lipid rafts 
in biological membranes. Annu Rev Cell Dev 
Biol 1998; 14: 111–136. 
 74 Brown D: Interactions between GPI-an-
chored proteins and membrane lipids. 
Trends Cell Biol 1992; 2: 338–343. 
 75 Varma R, Mayor S: GPI-anchored proteins 
are organized in submicron domains at the 
cell surface. Nature 1998; 394: 798–801. 
 76 Simons K, Ikonen E: Functional rafts in cell 
membranes. Nature 1997; 387: 569–572. 
 77 Brown DA, Rose JK: Sorting of GPI-an-
chored proteins to glycolipid-enriched 
membrane subdomains during transport to 
the apical cell surface. Cell 1992; 68: 533–544. 
 78 Munro S: Lipid rafts: elusive or illusive? Cell 
2003; 115: 377–388. 
 79 Simons K, Toomre D: Lipid rafts and signal 
transduction. Nat Rev Mol Cell Biol 2000; 1: 
 31–39. 
 80 Rajendran L, Simons K: Lipid rafts and 
membrane dynamics. J Cell Sci 2005; 118: 
 1099–1102. 
 81 Küng M, Bütikofer P, Brodbeck U, Stadel-
mann B: Expression of intracellular and 
GPI-anchored forms of GPI-specific phos-
pholipase D in COS-1 cells. Biochem Biophys 
Acta 1997; 1357: 329–338. 
 82 Bütikofer P, Kuypers FA, Xu CM, Chiu DTY, 
Lubin B: Enrichment of two glycosyl-phos-
phatidylinositol-anchored proteins, acetyl-
cholinesterase and decay accelerating factor, 
in vesicles released from human red blood 
cells. Blood 1989; 74: 1481–1489. 
 83 Hoener MC, Stieger S, Brodbeck U: Isolation 
and characterization of a phosphatidylinosi-
tol-glycan-anchor-specific phospholipase D 
from bovine brain. Eur J Biochem 1990; 190: 
 593–600. 
 84 Low MG, Huang KS: Factors affecting the 
ability of glycosylphosphatidylinositol-spe-
cific phospholipase D to degrade the mem-
brane anchors of cell surface proteins. Bio-
chem J 1991; 279: 483–488. 
 85 Müller G, Dearey E-A, Korndörfer A, Band-
low W: Stimulation of a glycosyl-phosphati-
dylinositol-specific phospholipase by insu-
lin and the sulfonylurea, glimepiride, in rat 
adipocytes depends on increased glucose 
transport. J Cell Biol 1994; 126: 1267–1276. 
 86 Müller G, Schulz A, Wied S, Frick W: Regu
lation of lipid raft proteins by glimepiride- 
and insulin-induced glycosylphosphati-
dylinositol-specific phospholipase C in rat 
adipocytes. Biochem Pharmacol 2005; 69: 
 761–780. 
 87 Müller G: The mode of action of glimepiri-de 
– beyond insulin secretion. Curr Med Chem 
2005; 5: 499–518. 
 88 Müller G, Wetekam E-M, Jung C, Bandlow 
W: Membrane association of lipoprotein li-
pase and a cAMP-binding ectoprotein in rat 
adipocytes. Biochemistry 1994;  33:  12149–
12159. 
 89 Eisenhaber B, Maurer-Stroh S, Novatchko-
va M, Schneider G, Eisenhaber F: Enzymes 
and auxiliary factors for GPI lipid anchor 
biosynthesis and post-translational trans-
fer to proteins. Bioessays 2003; 25: 367–385. 
 90 Shams-Eldin H, Azzouz N, Niehus S, Smith 
TK, Schwarz RT: An efficient method to ex-
press GPI-anchor proteins in insect cells. 
Biochem Biophys Res Commun 2008; 365: 
 657–663. 
 91 Walter EI, Ratnoff WD, Long KE, Kazura 
JW, Medof ME: Effect of glycoinositolphos-
pholipid anchor lipid groups on functional 
properties of decay-accelerating factor pro-
tein in cells. J Biol Chem 1992; 267: 1245–
1252. 
 92 Eberl H, Tittmann P, Glockshuber R: Char-
acterization of recombinant, membrane-at-
tached full-length prion protein. J Biol Chem 
2004; 279: 25058–25065. 
 93 Müller G, Bandlow W: Lipolytic membrane 
release of two phosphatidylinositol-an-
chored cAMP receptor proteins in yeast al-
ters their ligand-binding parameters. Arch 
Biochem Biophys 1994; 308: 504–514. 
 Müller
 
Pharmacology 2010;86:92–116 114
 94 Barboni E, Rivero BP, George AJ, Martin 
SR; Renoup DV, Hounsell EF, Barber PC, 
Morris RJ: The glycophosphatidylinositol 
anchor affects the conformation of Thy-1 
protein. J Cell Sci 1995; 108: 487–497. 
 95 Paulik MG, Wise AR, Forstner MB, Groves 
JT, Bertozzi CR: Synthetic analogues of gly-
cosylphosphatidylinositol-anchored pro-
teins and their behaviour in supported lipid 
bilayers. J Am Chem Soc 2007; 129: 11543–
11550. 
 96 Lehto MT, Sharom FJ: Proximity of the pro-
tein moiety of a GPI-anchored protein to 
the membrane surface: a FRET study. Bio-
chemistry 2002; 41: 8368–8376. 
 97 Yu J, Fischman DA, Steck TL: Selective sol-
ubilization of proteins and phospholipids 
from red blood cell membranes by nonion-
ic detergents. J Supramol Struct 1973; 1: 
 233–243. 
 98 Müller G, Korndörfer A, Saar K, Karbe-
Thönges B, Fasold H, Müllner S: 4  -Ami-
no-benzamido-taurocholic acid selectively 
solubilizes glycosyl-phosphatidylinositol-
anchored membrane proteins and im-
proves lipolytic cleavage of their membrane 
anchors by specific phospholipases. Arch 
Biochem Biophys 1994; 309: 329–340. 
 99 Premkumar DR, Fukuoka Y, Sevlever D, 
Brunschwig E, Rosenberry TL, Tykocinski 
ML: Properties of exogenously added GPI-
anchored proteins following their incorpo-
ration into cells. J Cell Biochem 2001; 82: 
 234–245. 
 100 Kooyman DL, Byrne GW, Logan JS: Glyco-
syl phosphatidylinositol anchor. Exp 
Nephrol 1998; 6: 148–151. 
 101 Medof ME, Nagarajan S, Tykocinski ML: 
Cell-surface engineering with GPI-an-
chored proteins. FASEB J 1996; 10: 574–586. 
 102 Civenni G, Test ST, Brodbeck U, Bütikofer 
P: In vitro incorporation of GPI-anchored 
proteins into human erythrocytes and their 
fate in the membrane. Blood 1998; 9: 11784–
11792. 
 103 McHugh RS, Ahmed SN, Wang YC, Sell 
KW, Selvavaj P: Construction, purification, 
and functional incorporation on tumor 
cells of glycolipid-anchored human B7-1 
(CD80). Proc Natl Acad Sci USA 1995; 92: 
 8059–8063. 
 104 McHugh RS, Nagarajan S, Wang YC, Sell 
KW, Selvaraj P: Protein transfer of glycosyl-
phosphatidylinositol-B7-1 into tumor cell 
membranes: a novel approach to tumor im-
munotherapy. Cancer Res 1999; 59: 2433–
2437. 
 105 Suzuki K, Okumura Y: GPI-linked proteins 
do not transfer spontaneously from eryth-
rocytes to liposomes. New aspects of reor-
ganization of the cell membrane. Biochem-
istry 2000; 39: 9477–9485. 
 106 Ilangumaran S, Robinson PJ, Hoessli DC: 
Transfer of exogenous glycosylinositol 
(GPI)-linked molecules to plasma mem-
branes. Trends Cell Biol 1996; 6: 163–169. 
 107 Zhang F, Schmidt WG, Hou Y, Williams 
AF, Jacobson K: Spontaneous incorpora-
tion of the glycosyl-phosphatidylinositol-
linked protein Thy-1 into cell membranes. 
Proc Natl Acad Sci USA 1992; 89: 5231–
5235. 
 108 Medof ME, Kinoshita T, Nussenzweig V: 
Inhibition of complement activation on the 
surface of cells after incorporation of de-
cay-accelerating factor (DAF) into their 
membranes. J Exp Med 1984; 160: 1558–
1578. 
 109 Olschewski D, Seidel R, Miesbauer M, 
Rambold AS, Oesterhelt D, Winklhofer KF, 
Tatzelt J, Engelhard M, Becker CF: Semi-
synthetic murine prion protein equipped 
with a GPI anchor mimic incorporates into 
cellular membranes. Chem Biol 2007; 14: 
 994–1006. 
 110 Kooyman DL, Byrne GW, Logan JS: Gly-
cosyl phosphatidylinositol anchor. Exp 
Nephrol 1998; 6: 148–151. 
 111 Müller G, Frick W: Signalling via caveolin: 
involvement in the cross-talk between 
phosphoinositolglycans and insulin. Cell 
Mol Life Sci 1999; 56: 945–970. 
 112 Müller G, Jung C, Wied S, Welte S, Jordan 
H, Frick W: Redistribution of glycolipid raft 
domain components induces insulin-mi-
metic signaling in rat adipocytes. Mol Cell 
Biol 2001; 21: 4553–4567. 
 113 Lisanti MP, Scherer PE, Tang ZL, Sargia-
como M: Caveolae, caveolin and caveolin-
rich membrane domains: a signalling hy-
pothesis. Trends Cell Biol 1994; 4: 231–238. 
 114 Mayor S, Rothberg KG, Maxfield FR: Se-
questration of GPI-anchor proteins in ca-
veolae triggered by cross-linking. Science 
1994; 264: 1948–1951. 
 115 Parton RG, Joggerst B, Simons K: Regulated 
internalization of caveolae. J Cell Biol 1994; 
 127: 1199–1215. 
 116 Zurzolo C, Lisanti MP, Caras IW, Nitsch L, 
Rodriguez-Boulan E: Glycosylphosphati-
dylinositol-anchored proteins are preferen-
tially targeted to the basolateral surface in 
Fischer rat thyroid epithelial cells. J Cell 
Biol 1993; 121: 1031–1039. 
 117 Fivaz M, Vilbois F, Thurnheer S, Pasquali 
C, Abrami L, Bickel PE, Parton RG, van
der Goot FG: Differential sorting and fate 
of endocytosed GPI-anchored proteins. 
EMBO J 2002; 21: 3989–4000. 
 118 Lakhan SE, Sabharanjak S, De A: Endocy-
tosis of glycosylphosphatidylinositol-an-
chored proteins. J Biomed Sci 2009; 16: 93 
DOI: 10.1186/1423-0127-16-93. 
 119 Deckert M, Ticchioni M, Bernard A: Endo-
cytosis of GPI-anchored proteins in human 
lymphocytes: role of glycolipid-based do-
mains, actin cytoskeleton, and protein ki-
nases. J Cell Biol 1996; 133: 791–799. 
 120 Sabharanjak S, Sharma P, Parton RG, May-
or S: GPI-anchored proteins are delivered to 
recycling endosomes via a distinct cdc42-
regulated, clathrin-independent pinocytic 
pathway. Dev Cell 2002; 2: 411–423. 
 121 Naslavsky N, Weigert R, Donaldson JG: 
Characterization of a nonclathrin endocy-
toc pathway: membrane cargo and lipid re-
quirements. Mol Biol Cell 2004; 15: 3542–
3552. 
 122 Zhang F, Crise B, Su B, Hou Y, Rose JK, 
Bothwell A, Jacobson K: Lateral diffusion 
of membrane-spanning and glycosylphos-
phatidylinositol-linked proteins: toward 
establishing rules governing the lateral mo-
bility of membrane proteins. J Cell Biol 
1991; 115: 75–86. 
 123 Keller GA, Siegel MW, Caras IW: Endocy-
tosis of glycophospholipid-anchored and 
transmembrane forms of CD4 by different 
endocytic pathways. EMBO J 1992; 11: 863–
874. 
 124 Bamezai A, Goldmacher VS, Rock KL: In-
ternalization of glycosylphosphatidylinosi-
tol (GPI)-anchored lymphocyte proteins. 
II. GPI-anchored and transmembrane mol-
ecules internalize through distinct path-
ways. Eur J Immunol 1992; 22: 15–21. 
 125 Müller G, Jung C, Wied S: Translocation of 
glycosylphosphatidylinositol-anchored 
proteins from plasma membrane microdo-
mains to lipid droplets in rat adipocytes is 
induced by palmitate, H 2 O 2 and the sulfo-
nylurea drug, glimepiride. Mol Pharmacol 
2008; 73: 1513–1529. 
 126 Müller G, Wied S, Jung C, Over S: Translo-
cation of glycosylphosphatidylinositol-an-
chored proteins to lipid droplets and in-
hibition of lipolysis in rat adipocytes is 
mediated by reactive oxygen species. Br J 
Pharmacol 2008; 154: 901–913. 
 127 Müller G, Wied S, Walz N, Jung C: Translo-
cation of glycosylphosphatidylinositol-an-
chored proteins from plasma membrane 
microdomains to lipid droplets in rat adi-
pocytes is induced by palmitate, H 2 O 2 and 
the sulfonylurea drug, glimepiride. Mol 
Pharmacol 2008; 73: 1513–1529. 
 128 Müller G, Over S, Wied S, Frick W: Asso-
ciation of (c)AMP-degrading glycosylphos-
phatidylinositol-anchored proteins with 
lipid droplets is induced by palmitate, H 2 O 2 
and the sulfonylurea drug, glimepiride, in 
rat adipocytes. Biochemistry 2008;  47: 
 1274–1287. 
 129 Müller G, Wied S, Over S, Frick W: Inhibi-
tion of lipolysis by palmitate, H 2 O 2 and the 
sulfonylurea drug, glimepiride, in rat adi-
pocytes depends on cAMP degradation by 
lipid droplets. Biochemistry 2008; 47: 1259–
1273. 
 130 Ducharme NA, Bickel PE: Lipid droplets in 
lipogenesis and lipolysis. Endocrinoloy 
2008; 149: 942–949. 
 131 Fujimoto T, Ohsaki Y, Cheng J, Suzuki M, 
Shinohara Y: Lipid droplets: a classic organ-
elle with new outfits. Histochem Cell Biol 
2008; 130: 263–279. 
 Transport of Glycolipid-Modified 
Proteins: Vision or Fiction? 
Pharmacology 2010;86:92–116 115
 132 Ohsaki Y, Cheng J, Suzuki M, Shinohara Y, 
Fujita A, Fujimoto T: Biogenesis of cyto-
plasmic lipid droplets: from the lipid ester 
globule in the membrane to the visible 
structure. Biochim Biophys Acta 2009; 
 1791: 399–407. 
 133 Cermelli S, Guo Y, Gross S, Welte M: The 
lipid-droplet proteome reveals that drop-
lets are a protein-storage depot. Curr Biol 
2006; 16: 1783–1795. 
 134 Boulant S, Targett-Adams P, McLauchlan J: 
Disrupting the association of hepatitis C vi-
rus core protein with lipid droplets corre-
lates with a loss in production of infectious 
virus. J Gen Virol 2007; 88: 2204–2213. 
 135 Miyanari Y, Atsuzawa K, Usada N, Watashi 
K, Hishiki T, Zayas M, Bartenschlager R, 
Wakita T, Hijikata T, Shimotohno K: The 
lipid droplet is an important organelle for 
hepatitis C virus production. Nat Cell Biol 
2007; 9: 1089–1097. 
 136 Cho SY, Shin ES, Park PJ, Shin DW, Chang 
HK, Kim D, Lee HH, Lee JH, Kim SH, 
Song MJ, Chang IS, Lee OS, Lee TR: Iden-
tification of mouse Prp19p as a lipid drop-
let protein. J Biol Chem 2007; 282: 2456–
2465. 
 137 Cocchiaro J, Kumar Y, Fischer E, Hackstadt 
T, Valdivia R: Cytoplasmic lipid droplets 
are translocated into the lumen of the  Chla-
mydia trachomatis parasitophorous vacu-
ole. Proc Natl Acad Sci USA 2008; 105: 
 9379–9384. 
 138 Ploegh HL: A lipid-based model for the 
creation of an escape hatch from the endo-
plasmic reticulum. Nature 2007; 448: 435–
438. 
 139 Aoki N, Jin-no S, Nakagawa Y, Asai N, Ara-
kawa E, Tamura N: Identification and char-
acterization of microvesicles secreted by 
3T3-L1 adipocytes: redox- and hormone-
dependent induction of milk fat globule-
epidermal growth factor 8-associated
microvesicles. Endocrinology 2007;  148: 
 3850–3862. 
 140 Müller G, Jung C, Straub J, Wied S, Kramer 
W: Induced release of membrane vesicles 
from rat adipocytes containing glyco-
sylphosphatidylinositol-anchored micro-
domain and lipid droplet signalling pro-
teins. Cell Signal 2009; 21: 324–338. 
 141 Müller G, Jung C, Wied S, Biemer-Daub G: 
Induced translocation of glycosylphospha-
tidylinositol-anchored proteins from lipid 
droplets to adiposomes in rat adipocytes. 
Br J Pharmacol 2009; 158: 749–770. 
 142 de Gassart A, Geminard C, Fevrier B, Ra-
poso G, Vidal M: Lipid raft-associated pro-
tein sorting in exosomes. Blood 2003; 102: 
 4336–4344. 
 143 Del Conde I, Shrimpton CN, Thiagarajan P, 
Lopez JA: Tissue-factor-bearing microvesi-
cles arise from lipid rafts and fuse with ac-
tivated platelets to initiate coagulation. 
Blood 2005; 106: 1604–1611. 
 144 Anderson SM, Yu G, Giattina M, Miller JL: 
Intercellular transfer of a glycosylphospha-
tidylinositol (GPI)-linked protein: release 
and uptake of CD4-GPI from recombinant 
adeno-associated virus-transduced HeLa 
cells. Proc Natl Acad Sci USA 1996; 93: 
 5894–5898. 
 145 Cauwenberghs S, Feijge MA, Harper AG, 
Sage SO, Curvers J, Heemskerk JW: Shed-
ding of procoagulant microparticles from 
unstimulated platelets by integrin-mediat-
ed destabilization of actin cytoskeleton. 
FEBS Lett 2006; 580: 5313–5320. 
 146 Scott RE, Perkins RG, Zschunke MA, Hoerl 
BJ, Maercklein PB: Plasma membrane ve-
siculation in 3T3 and SV3T3 cells. J Cell Sci 
1979; 35: 229–238. 
 147 Black PN: Shedding from normal and can-
cer-cell surfaces. N Engl J Med 1980; 303: 
 1415–1420. 
 148 Heijnen HF, Schiel AE, Fijnheer R, Geuze 
HJ, Sixma JJ: Activated platelets release two 
types of membrane vesicles: microvesicles 
by surface shedding and exosomes derived 
from exocytosis of multivesicular bodies 
and alpha-granules. Blood 1999; 94: 3791–
3799. 
 149 Piccin A, Murphy WG, Smith OP: Circulat-
ing microparticles: pathophysiology and 
clinical implications. Blood Rev 2007; 21: 
 157–171. 
 150 Denzer K, Kleijmeer MJ, Heijnen HF, 
Stoorvogel W, Geuze HJ: Exosome: from in-
ternal vesicle of the multivesicular body to 
intercellular signaling device. J Cell Sci 
2000; 113: 3365–3374. 
 151 Fevrier B, Raposo G: Exosomes: endosom-
al-derived vesicles shipping extracellular 
messages. Curr Opin Cell Biol 2004; 16: 
 415–421. 
 152 Keller S, Sanderson MP, Stoeck A, Altevogt 
P: Exosomes: from biogenesis and secretion 
to biological function. Immunol Lett 2006;  
 107: 102–108. 
 153 Pap E, Pallinger E, Pasztoi M, Falus A: 
Highlights of a new type of intercellular 
communication: microvesicle-based infor-
mation transfer. Inflamm Res 2009; 58: 1–8. 
 154 Stoorvogel W, Kleijmeer MJ, Geuze H, Ra-
poso G: The biogenesis and functions of 
exosomes. Traffic 2002; 3: 321–330. 
 155 Thery C, Zitvogel L, Amigorena S: Exo-
somes: composition, biogenesis and func-
tion. Nat Rev Immunol 2002; 3: 569–579. 
 156 Cocucci E, Racchetti G, Meldolesi J: Shed-
ding microvesicles: artefacts no more. 
Trends Cell Biol 2009; 19: 43–51. 
 157 Poste G, Nicolson GL: Arrest and metasta-
sis of blood-born tumor cells are modified 
by fusion of plasma membrane vesicles 
from highly metastatic cells. Proc Natl 
Acad Sci USA 1980; 77: 399–403. 
 158 Al-Nedawi K, Meehan B, Micallef J, Lhotak 
V, May L, Guha A, Rak J: Intercellular 
transfer of the oncogenic receptor EGFR-
vIII by microvesicles derived from tumour 
cells. Nature Cell Biol 2008; 10: 619–624. 
 159 Bastida E, Ordinas A, Escolar G, Jamieson 
GA: Tissue factor in microvesicles shed 
from U87MG human glioblastoma cells in-
duces coagulation, platelet aggregation, 
and thrombogenesis. Blood 1984; 64: 177–
184. 
 160 Freyssinet J-M: Cellular microparticles: 
what are they bad or good for? J Thromb 
Haemost 2003; 1: 1655–1662. 
 161 Gould SJ, Booth AM, Hildreth JE: The Tro-
jan exosome hypothesis. Proc Natl Acad Sci 
USA 2003; 100: 10592–10597. 
 162 Johnstone RM: Exosomes biological signif-
icance: a concise review. Blood Cells Mol 
Dis 2006; 36: 315–321. 
 163 Dunn DE, Yu J, Nagarajan S, Devetten M, 
Weichold FF, Medof ME, Young NS, Liu 
JM: A knock-out model of paroxysmal noc-
turnal hemoglobinuria: Pig-a(-) hemato-
poiesis is reconstituted following intercel-
lular transfer of GPI-anchored proteins. 
Proc Natl Acad Sci USA 1996; 93: 7938–
7943. 
 164 Medof ME, Kinoshita T, Silber R, Nussenz-
weig V: Amelioration of lytic abnormalities 
of paroxysmal nocturnal hemoglobinuria 
with decay accelerating factor. Proc Natl 
Acad Sci USA 1985; 82: 2980–2984. 
 165 Kooyman DL, Byrne GW, McClellan S, 
Nielsen D, Tone M, Waldmann H, Coffman 
TM, McCurry KR, Platt JL, Logan JS: In 
vivo transfer of GPI-linked complement re-
striction factors from erythrocytes to the 
endothelium. Science 1995; 269: 89–92. 
 166 Sloand EM, Mainwaring L, Keyvanfar K, 
Chen J, Maciejewski J, Klein HG, Young 
NS: Transfer of glycosylphosphatidyl-an-
chored proteins to deficient cells after 
erythrocyte transfusion in paroxysmal 
nocturnal hemoglobinuria. Blood 2004; 
 104: 3782–3788. 
 167 Liu T, Li R, Pan T, Liu D, Petersen RB, Wong 
BS, Gambetti P, Sy MS: Intercellular trans-
fer of the cellular prion protein. J Biol Chem 
2002; 277: 47671–47678. 
 168 Wolf P: The nature and significance of 
platelet products in human plasma. Br J 
Haematol 1967; 13: 269–288. 
 169 Sloand EM, Maciejewski JP, Dunn D, Moss 
J, Brewer B, Kirby M, Young NS: Correction 
of the PNH defect by GPI-anchored protein 
transfer. Blood 1998; 92: 4439–4445. 
 170 Müller G, Wied S, Jung C, Straub J: Coordi-
nated regulation of esterification and lipol-
ysis by palmitate, H 2 O 2 and the anti-diabet-
ic sulfonylurea drug, glimepiride, in rat 
adipocytes. Eur J Pharmacol 2008; 597: 6–
18. 
 171 Müller G, Wied S, Jung C, Biemer-Daub G, 
Frick W: Transfer of glycosylphosphati-
dylinositol-anchored 5  -nucleotidase CD73 
from adiposomes into rat adipocytes stim-
ulates lipid synthesis. Br J Pharmacol 2010; 
 160: 878–891. 
 Müller
 
Pharmacology 2010;86:92–116 116
 172 Müller G, Wied S, Jung C, Frick W, Biemer-
Daub G: Inhibition of lipolysis by adipo-
somes containing glycosylphosphati-
dylinositol-anchored Gce1 protein in rat 
adipocytes. Arch Physiol Biochem 2010; 
 116: 28–41. 
 173 Tso P, Balint J, Bishop M, Rodgers J: Acute 
inhibition of intestinal lipid transport by 
Pluronic L-81 in the rat. Am J Physiol Gas-
trointest Liver Physiol 1981,241:G487–
G497. 
 174 Phan CT, Tso P: Intestinal lipid absorption 
and transport. Front Biosci 2001; 6:d299–
d319. 
 175 Mansbach II CM, Gorelick FS: Develop-
ment of physiological regulation of intesti-
nal lipid absorption. II. Dietary lipid ab-
sorption, complex lipid synthesis, and the 
intracellular packaging and secretion of 
chylomicrons. Am J Physiol Gastrointesti-
nal Liver Physiol 2007; 293:G645–G650. 
 176 Wang Y, Iordanov H, Swietlicki EA, Wang 
L, Fritsch C, Coleman T, Semenkovich CF, 
Levin MS, Rubin DC: Targeted intestinal 
overexpression of the immediate early gene 
tis7 in transgenic mice increases triglycer-
ide absorption and adiposity. J Biol Chem 
2005; 280: 34764–34775. 
 177 Drover VA, Ajmal M, Nassir F, Davidson 
NO, Nauli AM, Sahoo D, Tso P, Abumrad 
NA: CD36 deficiency impairs intestinal lip-
id secretion and clearance of chylomicrons 
from the blood. J Clin Invest 2005; 115: 
 1290–1297. 
 178 Nakano T, Inoue I, Koyama I, Kanazawa K, 
Nakamura K-i, Narisawa S, Tanaka K, Aki-
ta M, Masuyama T, Seo M, Hokari S, Kata-
yama S, Alpers DH, Millan JL, Komoda T: 
Disruption of the murine intestinal alka-
line phosphatase gene Akp3 impairs lipid 
transcytosis and induces visceral fat accu-
mulation and hepatic steatosis. Am J Physi-
ol Gastrointest Liver Physiol 2007;  292: 
G1439–G1449. 
 179 Fielding BA, Callow J, Owen RM, Samra JS, 
Matthews DR, Frayn KN: Postprandial li-
pemia: the origin of an early peak studied 
by specific dietary fatty acid intake during 
sequential meals. Am J Clin Nutr 1996; 63: 
 36–41. 
 180 Jackson KG, Robertson MD, Fielding BA, 
Frayn KN, Williams CM: Olive oil increas-
es the number of triacylglycerol-rich chylo-
micron particles compared with other oils: 
an effect retained when a second standard 
meal is fed. Am J Clin Nutr 2002; 76: 942–
949. 
 181 Mansbach II CM, Nevin P: Intracellular 
movement of triacylglycerols in the intes-
tine. J Lipid Res 1998; 39: 963–968. 
 182 Tso P, Balint JA, Rodgers JB: Effect of hy-
drophobic surfactant (Pluronic L-81) on 
lymphatic lipid transport in the rat. Am J 
Physiol Gastrointest Liver Physiol 1980; 
 239:G348–G353. 
 183 Mansbach II CM, Dowell R: Effect of in-
creasing lipid loads on the ability of the en-
doplasmic reticulum to transport lipid to 
the Golgi. J Lipid Res 2000; 41: 605–612. 
 184 Cartwright IJ, Plonne D, Higgins JA: Intra-
cellular events in the assembly of chylomi-
crons in rabbit enterocytes. J Lipid Res 
2000; 41: 1728–1739. 
 185 Robertson M, Parkes M, Warren B, Fergu-
son D, Jackson K, Jewell D, Frayn K: Mo-
bilisation of enterocyte fat stores by oral 
glucose in humans. Gut 2003; 52: 834–839. 
 186 Murphy DJ: The biogenesis and functions 
of lipid bodies in animals, plants and mi-
croorganisms. Prog Lipid Res 2001; 40: 325–
438. 
 187 Zhu J, Lee B, Buhman KK, Cheng JX: A dy-
namic, cytoplasmic triacylglycerol pool in 
enterocytes revealed by  ex vivo and in vivo 
coherent anti-Stokes Raman scattering im-
aging. J Lipid Res 2009; 50: 1080–1089. 
 188 Listenberger LL, Han X, Lewis SE, Cases S, 
Farese RVJ, Ory DS, Schaffer JE: Triglycer-
ide accumulation protects against fatty ac-
id-induced lipotoxicity. Proc Natl Acad Sci 
USA 2003; 100: 3077–3082. 
 189 Gibbons GF, Islam K, Pease RJ: Mobilisa-
tion of triacylglycerol stores. Biochim Bio-
phys Acta 2000; 1483: 37–57. 
 190 Danielsen EM, Hansen GH: Lipid raft orga-
nization and function in the small intesti-
nal brush border. J Physiol Biochem 2008; 
 64: 377–382. 
 191 Danielsen EM, Hansen GH: Lipid raft orga-
nization and function in brush borders of 
epithelial cells. Mol Membr Biol 2006; 23: 
 71–79. 
 192 Lee B, Zhu J, Wolins NE, Cheng JX, Buh-
man KK: Differential association of adi-
pophilin and TIP47 proteins with cytoplas-
mic lipid droplets in mouse enterocytes 
during dietary fat absorption. Biochim Bio-
phys Acta 2009; 1791: 1173–1180. 
 193 Bütikofer P, Brodbeck U: Partial purifica-
tion and characterization of a (glycosyl) 
inositol phospholipid-specific phospholi-
pase C from peanut. J Biol Chem 1993; 268: 
 17794–17799. 
 194 Küng M, Bütikofer P, Brodbeck U, Stadel-
mann B: Expression of intracellular and 
GPI-anchored forms of GPI-specific phos-
pholipase D in COS-1 cells. Biochim Bio-
phys Acta 1997; 1357: 329–338. 
 195 Müller G, Hanekop N, Wied S, Frick W: 
Cholesterol depletion blocks redistribution 
of lipid raft components and insulin-mi-
metic signaling by glimepiride and phos-
phoinositolglycans in rat adipocytes. Mol 
Med 2002; 8: 120–136. 
 196 Müller G, Petry S: Triacylglycerol, storage 
and mobilization of human; in Meyers A 
(ed): Encyclopedia in Biochemistry and 
Molecular Biology. Weinheim, Wiley VCH, 
2005, vol 14, pp 621–704. 
 197 Iyer H, Khedkar A, Verma M: Oral insulin 
– a review of current status. Diabetes Obe-
sity Metabol 2010; 12: 179–185. 
 198 Kapitza C, Zijlstra E, Heinemann L, Cas-
telli MC, Riley G, Heise T: Oral insulin: a 
comparison with subcutaneous regular hu-
man insulin in patients with type 2 diabe-
tes. Diabetes Care 2010; 33: 1288–1290. 
 199 Heinemann L, Jacques Y: Oral insulins and 
buccal insulins: a critical repraisal. J Diabe-
tes Sci Technol 2009; 3: 568–584. 
 200 Billingsley ML: Druggable targets and tar-
geted drugs: enhancing the development of 
new therapeutics. Pharmacology 2008; 82: 
 239–244. 
 
